2. Amyotrophic lateral sclerosis Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
Drugs and their primary sponsors and trial info
(2R)-2-Propyloctanoic acid
ONO Pharmaceutical Co., Ltd.
2008 Phase 2 EUCTR2007-004723-37-FR Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-GB Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-DE Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-BE Belgium;France;Germany;United Kingdom;
ONO Pharmaceutical Co.,Ltd
2007 - EUCTR2006-002660-26-NL Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2007 - EUCTR2006-002660-26-GB Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 Phase 2 EUCTR2006-002660-26-FR Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-DE Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-BE Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-AT Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
(6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate
Biogen Idec Limited
2011 Phase 3 EUCTR2010-022818-19-ES Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;
(R)-(-)-2-Propyloctaroic acid
ONO PHARMA UK LTD
2004 - EUCTR2004-002912-27-ES Spain;
201600930
The University of Queensland
2021 Phase 2 EUCTR2020-005018-17-NL Australia;Netherlands;
3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one.
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
3K3A-APC Protein
Macquarie University, Australia
2021 Phase 2 NCT05039268 Australia;
4 cholesten-3-one, oxime
TROPHOS
2011 - EUCTR2010-021179-10-GB Germany;Spain;United Kingdom;
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base
AB SCIENCE
2021 Phase 3 EUCTR2019-001862-13-IT Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
4-cholesten-3-one, oxime
TROPHOS
2009 Phase 2;Phase 3 EUCTR2008-007320-25-GB Belgium;France;Germany;Spain;United Kingdom;
TROPHOS SA
2011 Phase 2;Phase 3 EUCTR2010-021179-10-BE Belgium;Germany;Spain;United Kingdom;
2011 - EUCTR2010-021179-10-DE Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-FR Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-BE Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-007320-25-ES Belgium;France;Germany;Spain;United Kingdom;
2009 - EUCTR2008-007320-25-DE Belgium;France;Germany;Spain;United Kingdom;
6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
CYTOKINETICS, INC.
2016 Phase 3 EUCTR2014-005413-23-IT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Cytokinetics Inc
2013 Phase 2 EUCTR2012-004987-23-GB Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-004987-23-ES Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-IE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-DE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
- - EUCTR2012-004987-23-NL Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
Cytokinetics, Inc.
2017 Phase 3 EUCTR2016-002629-13-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-FR Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-ES Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-ES Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-DE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005413-23-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
Retrotope, Inc.
2021 Phase 2 EUCTR2020-003962-38-SE Estonia;Netherlands;Sweden;
2021 Phase 2 EUCTR2020-003962-38-NL Estonia;Netherlands;Sweden;
2021 Phase 2 EUCTR2020-003962-38-EE Estonia;Netherlands;Sweden;
AB 1003
AB SCIENCE
2021 Phase 3 EUCTR2019-001862-13-IT Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
AB1010
AB SCIENCE
2021 Phase 3 EUCTR2019-001862-13-IT Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2015 - EUCTR2010-024423-24-IT Argentina;Colombia;France;Germany;Greece;Hungary;Italy;Mexico;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;
AB Science
2022 Phase 3 EUCTR2019-001862-13-GR Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001862-13-DK Argentina;Belgium;Canada;Denmark;France;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-PL Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2019-001862-13-IE Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2019-001862-13-GB Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2010-024423-24-IE Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
ABScience
2022 Phase 3 EUCTR2019-001862-13-PT Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001862-13-NO Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-SI Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-SE Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-ES Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-PT Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-NL Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-HU Argentina;Belgium;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-GR Argentina;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;United States;
2014 Phase 2;Phase 3 EUCTR2010-024423-24-SK Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2010-024423-24-ES France;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;
ABBV-CLS-7262
Calico Life Sciences LLC
2021 Phase 1 NCT04948645 Canada;United States;
ACIDO TAUROURSODESOSSICOLICO
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2018-002722-22-IT Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom;
AL001
Alector Inc.
2021 Phase 2 NCT05053035 United States;
ALPHA-LIPOIC ACID
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2006 - EUCTR2005-005152-40-IT Italy;
ALXN1210
ALEXION PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2019-004619-30-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Alexion Pharmaceuticals
2020 Phase 3 EUCTR2019-004619-30-SE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
ALZT-OP1a (cromolyn)
AZTherapies, Inc.
2020 Phase 2 NCT04428775 United States;
AMSC
Bioinova, s.r.o.
2012 Phase 2 EUCTR2011-000362-35-CZ Czech Republic;
AMX0035
AMYLYX PHARMACEUTICALS Inc.
2021 Phase 3 EUCTR2021-000250-26-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Amylyx Pharmaceuticals Inc.
2022 Phase 3 EUCTR2021-000250-26-PL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2022 - NCT05286372 -
2021 Phase 3 NCT05021536 Puerto Rico;United States;
2021 Phase 3 EUCTR2021-000250-26-SE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 2/Phase 3 NCT04516096 United States;
2018 Phase 2 NCT03488524 United States;
2017 Phase 2/Phase 3 NCT03127514 United States;
ANX005
Annexon Biosciences
2021 Phase 2 EUCTR2021-000325-26-FR Canada;France;United States;
Annexon, Inc.
2021 Phase 2 NCT04569435 Canada;France;United States;
AP-101
AL-S Pharma
2021 Phase 2 NCT05039099 Canada;Germany;Korea, Republic of;Sweden;United States;
2019 Phase 1 NCT03981536 Canada;
APL-2
APELLIS PHARMACEUTCIALS, INC.
2021 Phase 2 EUCTR2019-003797-10-IT Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Apellis Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2019-003797-10-NL Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2019-003797-10-IE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2019-003797-10-DE Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2019-003797-10-CZ Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
APO-P001
Apodemus AB
2014 Phase 2 EUCTR2012-002099-15-SE Sweden;
AT-1501
Anelixis Therapeutics, LLC
2020 Phase 2 NCT04322149 Canada;United States;
AVP-923
Avanir Pharmaceuticals
2001 Phase 3 NCT00021697 United States;
AZILECT® 1 mg Tabletten
Universitätsklinikum Ulm
2013 Phase 2 EUCTR2011-004482-32-DE Germany;
Abacavir
Stichting TRICALS Foundation
2021 Phase 3 EUCTR2020-005069-15-NL Australia;Netherlands;United Kingdom;
Acetylcarnitine
IST. DI RICERCHE FARMACOLOG. M. NEGRI
2005 - EUCTR2004-004158-23-IT Italy;
Acthar
Mallinckrodt
2017 Phase 2/Phase 3 NCT03068754 Argentina;Canada;Chile;Colombia;Mexico;Peru;United States;
Actos
University Hospital of Ulm
2008 - EUCTR2006-005410-13-DE Germany;
Albumin
Instituto Grifols, S.A.
2014 Phase 2 NCT02479802 Spain;
Albutein
Grifols Therapeutics LLC
2016 Phase 2 NCT02872142 United States;
Instituto Grifols S.A.
2014 Phase 4 EUCTR2013-004842-40-ES Spain;
Albúmina humana
Instituto Grifols S.A.
2014 Phase 4 EUCTR2013-004842-40-ES Spain;
All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-P-thioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidine
Ionis Pharmaceuticals, Inc.
- Phase 1;Phase 2;Phase 3 EUCTR2020-005522-28-BE Belgium;Canada;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Turkey;United Kingdom;United States;
All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-Pthioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-
IONIS PHARMACEUTICALS, INC.
- Phase 1;Phase 3 EUCTR2020-005522-28-IT Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Turkey;United Kingdom;United States;
AlloRx
The Foundation for Orthopaedics and Regenerative Medicine
2022 Phase 1 NCT05003921 Antigua and Barbuda;
Amivita
Wujin People's Hospital
2017 - NCT03103815 China;
Anakinra
Charite University, Berlin, Germany
2011 Phase 2 NCT01277315 Germany;
Arimoclomol
CytRx
2008 Phase 2 NCT00561366 Canada;United States;
2005 Phase 2 NCT00244244 United States;
Orphazyme
2019 Phase 3 NCT03836716 Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 NCT03491462 Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
University of Miami
2009 Phase 2/Phase 3 NCT00706147 United States;
AstroRx
Kadimastem
2018 Phase 1/Phase 2 NCT03482050 Israel;
Autologous Adipose-derived Mesenchymal Stromal Cells
Mayo Clinic
2017 Phase 2 NCT03268603 United States;
Autologous MSC-NTF cells
Brainstorm-Cell Therapeutics
2014 Phase 2 NCT02017912 United States;
Autologous Mesenchymal stem cells (MSCs)
Hospital e Maternidade Dr. Christóvão da Gama
2015 Phase 1 NCT02987413 Brazil;
Autologous T-regulatory lymphocytes
Stanley H. Appel, MD
2016 Phase 1 NCT03241784 United States;
Autologous adult bone marrow mononuclear cells (BM-MNC) unexpanded
Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
2019 Phase 2 EUCTR2019-002302-46-ES Spain;
Autologous adult bone marrow mononuclear cells unexpanded
Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
2019 Phase 2 EUCTR2019-002302-46-ES Spain;
Autologous bone marrow mononucleated cells
Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)
2014 - EUCTR2011-004801-25-ES Spain;
Autologous bone marrow-derived stem cells
TCA Cellular Therapy
2010 Phase 1 NCT01082653 United States;
Autologous mesenchymal stem cells
Mayo Clinic
2012 Phase 1 NCT01609283 United States;
2010 Phase 1 NCT01142856 United States;
BHV-0223
Biohaven Pharmaceuticals, Inc.
2018 Phase 1 NCT03520517 United States;
BIIB050 / KNS-760704
Biogen Idec Limited
2011 Phase 3 EUCTR2010-022818-19-ES Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2010-022818-19-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-SE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-NL Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-IE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-GB Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-DE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
BIIB050/KNS-760704
Biogen Idec Research Limited
2012 Phase 3 EUCTR2011-006119-70-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-SE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-NL Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-IE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-GB Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-ES Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-DE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
BIIB067
Biogen
2017 Phase 3 NCT03070119 Belgium;Canada;France;Germany;Italy;Japan;New Zealand;United Kingdom;United States;
2016 Phase 3 NCT02623699 Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Sweden;United Kingdom;United States;
BIIB067 (ISIS666853)
BIOGEN IDEC RESEARCH LIMITED
2022 Phase 3 EUCTR2020-004590-51-IT Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2016-003225-41-IT Australia;Belgium;Canada;Denmark;European Union;Germany;Italy;Japan;Poland;Spain;United Kingdom;United States;
Biogen Idec Research Limited
2021 Phase 3 EUCTR2020-004590-51-FR Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004590-51-ES Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004590-51-DE Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2016-003225-41-ES Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2016-003225-41-PL Argentina;Australia;Belgium;Canada;Denmark;European Union;Germany;Japan;Korea, Republic of;Poland;United Kingdom;United States;
2020 Phase 3 EUCTR2016-003225-41-DK Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2015-004098-33-PL Argentina;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Sweden;United Kingdom;United States;
2020 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-DK Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003225-41-DE Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003225-41-BE Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2017 Phase 1;Phase 3 EUCTR2016-003225-41-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-SE Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-GB Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-DE Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-BE Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
BIIB067 (Tofersen)
Biogen
2021 Phase 3 NCT04856982 Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
BIIB078
Biogen
2020 Phase 1 NCT04288856 Canada;Netherlands;Switzerland;United Kingdom;United States;
2018 Phase 1 NCT03626012 Canada;Ireland;Netherlands;Switzerland;United Kingdom;United States;
BIIB100
Biogen
2019 Phase 1 NCT03945279 United States;
BIIB105
Biogen
2020 Phase 1 NCT04494256 Canada;Italy;Netherlands;United States;
BLZ945
Novartis Pharma AG
2019 Phase 2 EUCTR2019-000826-22-SE Finland;Sweden;United States;
2019 Phase 2 EUCTR2019-000826-22-FI Finland;Sweden;United States;
Novartis Pharmaceuticals
2019 Phase 2 NCT04066244 Finland;Sweden;United States;
BOTOX 100 UNITES ALLERGAN (PR1)
Hospices Civils de Lyon
2011 Phase 2 EUCTR2010-023161-21-FR France;
BRX-345
ORPHAZYME APS
2019 Phase 3 EUCTR2019-000374-39-IT Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-IT Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Orphazyme A/S
2019 Phase 3 EUCTR2019-000374-39-SE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000374-39-PL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000374-39-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000374-39-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000374-39-ES Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000374-39-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-SE Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-PL Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-NL Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-GB Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-FR Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-ES Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-BE Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Baclofen
AZIENDA OSPEDALIERO-UNIVERSITARIA
2010 - EUCTR2010-020257-13-IT Italy;
Barium
Milton S. Hershey Medical Center
2022 - NCT04889898 United States;
Basiliximab
Emory University
2013 Phase 2 NCT01884571 United States;
Beta Hydroxybutyrate
University of Ulm
2021 Phase 2 NCT04820478 Germany;
Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
Edward Kasaraskis
2017 Early Phase 1 NCT03707795 United States;
Biotin
American University of Beirut Medical Center
2018 Phase 2 NCT03427086 Lebanon;
Blood sample and environmental survey
Centre Hospitalier Universitaire de Pointe-a-Pitre
2014 - NCT03367650 Guadeloupe;Martinique;
Bosutinib
Center for iPS Cell Research and Application, Kyoto University
2019 Phase 1 JPRN-UMIN000036295 Japan;
Inoue Haruhisa
2019 Phase 1 JPRN-jRCT2051190001 Japan;
Kyoto University
2019 Phase 1 NCT04744532 Japan;
Botox injection
Hospices Civils de Lyon
2012 Phase 2 NCT01551940 France;
Botulinum toxin type B (Myobloc)
The University of Texas Health Science Center at San Antonio
2003 Phase 2/Phase 3 NCT00125203 United States;
Butylphthalide
Peking Union Medical College Hospital
2015 - ChiCTR-IPR-15007365 China;
CARBOLITHIUM
I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX
2007 - EUCTR2007-002379-16-IT Italy;
ISTITUTO SUPERIORE DI SANITA`
2009 - EUCTR2008-006722-34-IT Italy;
CARBOLITHIUM*100CPS
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2008 - EUCTR2008-001094-15-IT Italy;
CC100
Chemigen, LLC
2017 Phase 1 NCT03049046 United States;
CK-2017357
CYTOKINETICS, INC.
2016 Phase 3 EUCTR2014-005413-23-IT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Cytokinetics
2012 Phase 2 NCT01709149 Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2011 Phase 2 NCT01486849 United States;
2010 Phase 2 NCT01089010 United States;
Cytokinetics, Inc.
2017 Phase 3 EUCTR2016-002629-13-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-FR Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-ES Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-ES Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-DE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005413-23-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
CK-2017357 (Part A)
Cytokinetics
2011 Phase 2 NCT01378676 United States;
CK-2017357 (Part B)
Cytokinetics
2011 Phase 2 NCT01378676 United States;
CK-2127107
CYTOKINETICS, INC.
2021 Phase 3 EUCTR2020-004040-29-IT Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
Cytokinetics Inc
2022 Phase 3 EUCTR2020-004040-29-PT Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004040-29-SE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004040-29-NL Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004040-29-IE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004040-29-ES Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004040-29-FR Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004040-29-DE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004040-29-BE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
Cytokinetics, Inc.
2018 Phase 2 EUCTR2018-000586-37-NL Australia;Canada;Ireland;Netherlands;Spain;United States;
2018 Phase 2 EUCTR2018-000586-37-IE Australia;Canada;Ireland;Netherlands;Spain;United States;
2018 Phase 2 EUCTR2018-000586-37-ES Australia;Canada;Ireland;Netherlands;Spain;United States;
CK2017357
Cytokinetics Inc
2013 Phase 2 EUCTR2012-004987-23-GB Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-004987-23-ES Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-IE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-DE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
- - EUCTR2012-004987-23-NL Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
CNM-Au8
Clene Nanomedicine
2022 - NCT05281484 United States;
2019 Phase 2 NCT04098406 Australia;
2019 - NCT04081714 United States;
Merit E. Cudkowicz, MD
2020 Phase 2/Phase 3 NCT04414345 United States;
2020 Phase 2/Phase 3 NCT04297683 United States;
COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
2018 Phase 2 EUCTR2017-004459-21-IT Italy;
Caffeine
Genentech, Inc.
2016 Phase 1 NCT02655614 Canada;Netherlands;United States;
Calogen
University of Ulm
2015 - NCT02306590 Germany;
Cannabis Sativa extract Oromucosal spray
Ospedale San Raffaele
2013 Phase 2/Phase 3 NCT01776970 Italy;
Cannabis, Medical
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Capsaicin
University of Florida
2016 Early Phase 1 NCT02710162 United States;
2016 Early Phase 1 NCT02710110 United States;
Capsaicin Challenge
University of Florida
2017 - NCT02962050 United States;
Carbidopa-levodopa
Washington University School of Medicine
2019 Phase 1 NCT03929068 United States;
Carbonate de lithium
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-003707-32-FR France;
Ceftriaxone
AZIENDA OSPEDALIERA PISANA
2007 - EUCTR2007-004165-17-IT Italy;
Massachusetts General Hospital
2006 Phase 3 NCT00349622 Canada;Puerto Rico;United States;
Celecoxib
Columbia University
2006 Phase 2 NCT00355576 United States;
Cell-based therapeutics
Pomeranian Medical University Szczecin
2010 Phase 1 NCT02193893 Poland;
Cell-based therapy
University of Warmia and Mazury
2015 Phase 1 NCT02881489 -
2015 Phase 1 NCT02881476 -
Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients
Mossakowski Medical Research Centre Polish Academy of Sciences
2015 Phase 1 NCT03296501 Poland;
Cimetidine plus Dexpramipexole
Knopp Biosciences
2012 Phase 1 NCT01536249 United States;
Cistanche Total Glycosides
Peking University
2008 Phase 2 NCT00753571 China;
Clenbuterol
Dwight Koeberl, M.D., Ph.D.
2020 Phase 2 NCT04245709 United States;
Coenzyme Q10
Columbia University
2005 Phase 2 NCT00243932 United States;
Colchicine 1 MG Oral Tablet
Azienda Ospedaliero-Universitaria di Modena
2019 Phase 2 NCT03693781 Italy;
Combination Product: Active treatment with dual therapy
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
2016 Phase 2 NCT03204500 Mexico;
Control group
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 - NCT04518540 China;
Copegus
Apodemus AB
2014 Phase 2 EUCTR2012-002099-15-SE Sweden;
Creatine
Columbia University
2006 Phase 2 NCT00355576 United States;
National Center for Research Resources (NCRR)
2000 Phase 2 NCT00005674 United States;
Nazem Atassi
2011 Phase 2 NCT01257581 United States;
Creatine Monohydrate
The Avicena Group
2003 Phase 3 NCT00069186 United States;
Creatine monohydrate
National Center for Complementary and Integrative Health (NCCIH)
2002 Phase 2 NCT00070993 United States;
Creatinine
National Center for Research Resources (NCRR)
2000 Phase 2 NCT00005766 United States;
Cu(II)ATSM
Collaborative Medicinal Development Pty Limited
2020 Phase 2 NCT04313166 Australia;
2019 Phase 2/Phase 3 NCT04082832 Australia;
2018 Phase 1/Phase 2 NCT03136809 Australia;
2016 Phase 1 NCT02870634 Australia;
Células Mesenquimales de tejido adiposo
FUNDACIÓN PROGRESO Y SALUD
2013 - EUCTR2011-006254-85-ES Spain;
Células madre mesenquimales de tejido adiposo autólogo
FUNDACIÓN PROGRESO Y SALUD
2013 - EUCTR2011-006254-85-ES Spain;
Células troncales hematopoyéticas autólogas adultas extraidas de médula ósea
Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)
2014 - EUCTR2011-004801-25-ES Spain;
DEXTRAN SULFATE SODIUM
TikoMed AB
2018 Phase 2 EUCTR2017-005065-47-SE Sweden;
DNL343
Denali Therapeutics Inc.
2021 Phase 1 NCT05006352 Netherlands;United States;
DNL747
Sanofi
2018 Phase 1 NCT03757351 Netherlands;United States;
Daraprim
Weill Medical College of Cornell University
2013 - EUCTR2011-004798-99-DE Germany;Italy;United States;
Darunavir
National Institute of Neurological Disorders and Stroke (NINDS)
2019 Phase 1 NCT02437110 United States;
Deferiprone
University Hospital, Lille
2019 Phase 2/Phase 3 NCT03293069 France;
2013 Phase 2 NCT02164253 France;
2011 - NCT02880033 France;
Deferiprone DR
centre hospitalier universitaire de Lille
2018 Phase 3 EUCTR2017-003763-35-FR France;
Dexdor
Turku University Hospital
2018 Phase 4 EUCTR2018-000142-18-FI Finland;
Dexpramipexole
Biogen Idec Limited
2011 Phase 3 EUCTR2010-022818-19-ES Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;
Biogen Idec Research Limited
2012 Phase 3 EUCTR2011-006119-70-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-SE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-NL Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-IE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-GB Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-ES Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-DE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
Knopp Biosciences
2012 Phase 3 NCT01622088 Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 Phase 1 NCT01511029 United States;
2011 Phase 3 NCT01281189 Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 1 NCT01449578 United States;
Dexpramipexole (dose 1)
Knopp Biosciences
2011 Phase 1 NCT01424176 United States;
Dexpramipexole (dose 2)
Knopp Biosciences
2011 Phase 1 NCT01424176 United States;
Dexpramipexole Dichydrochloride
Biogen Idec Limited
2011 Phase 3 EUCTR2010-022818-19-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-SE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-NL Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-IE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-GB Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
Dexpramipexole Dihydrochloride
Biogen Idec Limited
2011 - EUCTR2010-022818-19-DE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
Dextran Sodium Sulfur Salt 5, Mw 5 kDa. a type of Low Molecular Weight Dextran Sulfate (LMW-DS)
University of Birmingham
2018 Phase 2 EUCTR2018-000668-28-GB United Kingdom;
Dextromethorphan HBr and quinidine sulfate
University of Florida
2019 Phase 1/Phase 2 NCT03883581 United States;
Dextromethorphan hydrobromide 20 mg and quinidine sulfate
Avanir Pharmaceuticals
2007 Phase 3 NCT00573443 Argentina;Brazil;United States;
Dextromethorphan hydrobromide 30 mg and quinidine sulfate
Avanir Pharmaceuticals
2007 Phase 3 NCT00573443 Argentina;Brazil;United States;
Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone
Milton S. Hershey Medical Center
2022 - NCT04889898 United States;
Dolutegravir
National Institute of Neurological Disorders and Stroke (NINDS)
2019 Phase 1 NCT02437110 United States;
Stichting TRICALS Foundation
2021 Phase 3 EUCTR2020-005069-15-NL Australia;Netherlands;United Kingdom;
Dronabinol
Cantonal Hospital of St. Gallen
2005 - NCT00812851 Switzerland;
Dutasterida
Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
2021 Phase 2 EUCTR2021-001989-38-ES Spain;
E0302 (mecobalamin)
Eisai Co., Ltd.
2008 Phase 2/Phase 3 NCT00445172 Japan;
2007 Phase 2/Phase 3 NCT00444613 Japan;
EBIXA
Jorge Matias-Guiu Guia
2008 - EUCTR2007-002117-39-ES Spain;
EH301 (Nicotinamide Riboside/Pterostilbene)
Haukeland University Hospital
2020 - NCT04562831 Norway;
EPI-589
Fujita Koji
2021 Phase 2 JPRN-jRCT2061210031 Japan;
Hamatani Tatsuto
2021 Phase 1 JPRN-jRCT2071210023 Japan;
2018 Phase 1 JPRN-jRCT2071210022 Japan;
PTC Therapeutics
2016 Phase 2 NCT02460679 United States;
EPREX IV SC 1FL 1ML 40000 UI
ISTITUTO NEUROLOGICO CARLO BESTA
2005 - EUCTR2005-005873-31-IT Italy;
EPREX*1SIR 40000UI/ML 1ML
ISTITUTO NEUROLOGICO CARLO BESTA
2011 - EUCTR2011-001329-26-IT Italy;
2010 - EUCTR2009-016066-91-IT Italy;
Edaravone
Ehime University Hospital
2015 Phase 1,2 JPRN-UMIN000016352 Japan;
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Ferrer Internacional, S.A.
2021 Phase 3 EUCTR2020-003376-40-IE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
Isfahan University of Medical Sciences
2017 Phase 2/Phase 3 NCT03272802 Iran, Islamic Republic of;
Kondo Kazuoki
2022 Phase 3 JPRN-jRCT2071210117 Canada;Germany;Italia;Japan;South Korea;Switzerland;US;
2021 Phase 3 JPRN-jRCT2031200301 Canada;France;Germany;Italy;Japan;Korea;Switzerland;United States of America;
2021 Phase 1 JPRN-jRCT2031200361 Japan;
2020 Phase 3 JPRN-jRCT2041200084 Canada;France;Germany;Italy;Japan;United States of America;
Mitsubishi Tanabe Development America Inc.
2021 Phase 3 EUCTR2019-004256-11-IT Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
2020 Phase 3 EUCTR2019-002108-41-IT Canada;France;Germany;Italy;Japan;United States;
Mitsubishi Tanabe Pharma America Inc.
2019 - NCT04259255 Canada;United States;
Okayama university
2016 - JPRN-UMIN000024854 Japan;
Electrical Impedance Myography
University of Florida
2016 Early Phase 1 NCT02710162 United States;
Endocannabinoid palmitoylethanolamide (PEA)
University of Roma La Sapienza
2014 - NCT02645461 -
Engensis
Helixmith Co., Ltd.
2021 Phase 2 NCT04632225 Korea, Republic of;United States;
Enoxacin
McGill University
2021 Phase 1/Phase 2 NCT04840823 Canada;
Eril®
Georg-August-Universität Göttingen
2019 Phase 2 EUCTR2017-003676-31-FR France;Germany;Switzerland;
Erythropoetin (EPO)
University Hospital Muenster
2006 Phase 2 NCT00298597 Germany;
Erythropoietin
ISTITUTO NEUROLOGICO CARLO BESTA
2005 - EUCTR2005-005873-31-IT Italy;
ISTITUTO NEUROLOGICO CARLO BESTA
2010 - EUCTR2009-016066-91-IT Italy;
Escitalopram
University of South Carolina
2009 Phase 3 NCT00965497 United States;
Ezogabine
Brian Wainger
2015 Phase 2 NCT02450552 United States;
F 18 T807
Tammie L. S. Benzinger, MD, PhD
2015 - NCT02414230 United States;
FAB122
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Ferrer Internacional, S.A.
2022 Phase 3 EUCTR2020-003376-40-SE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
2021 Phase 3 EUCTR2020-003376-40-PL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
2021 Phase 3 EUCTR2020-003376-40-IE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
2021 Phase 3 EUCTR2020-003376-40-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2021 Phase 3 EUCTR2020-003376-40-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
2021 Phase 3 EUCTR2020-003376-40-BE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
FASUDIL HYDROCHLORIDE
Georg-August-Universität Göttingen
2019 Phase 2 EUCTR2017-003676-31-FR France;Germany;Switzerland;
FLX-787-ODT
Flex Pharma, Inc.
2018 Phase 1/Phase 2 NCT03334786 United States;
FLX-787-ODT (orally disintigrating tablet)
Flex Pharma, Inc.
2017 Phase 1/Phase 2 NCT03338114 United States;
FamC-1
Polski Bank Komórek Macierzystych JSC (PBKM)
2020 Phase 1;Phase 2 EUCTR2018-004171-12-PL Poland;
Fasudil
Peking University Third Hospital
2013 Phase 2 NCT01935518 China;
University Medical Center Goettingen
2019 Phase 2 NCT03792490 France;Germany;Switzerland;
Fasudil (WP-0512)
Woolsey Pharmaceuticals
2021 Phase 2 NCT05218668 Australia;United States;
Febuxostat
Teikyo University
2017 - JPRN-UMIN000029308 Japan;
Tsukuba International Clinical Pharmacology Clinic
2016 - JPRN-UMIN000024312 Japan;
Fecal microbiota transplantation
Azienda Ospedaliero-Universitaria di Modena
2020 - NCT03766321 Italy;
Fenilbutirato
Amylyx Pharmaceuticals Inc.
2021 Phase 3 EUCTR2021-000250-26-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Fig
FeGALS
2009 - JPRN-UMIN000008527 Japan;
Filgrastim
MinYoung Kim, M.D.
2014 - NCT02236065 Korea, Republic of;
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
2014 Phase 2 EUCTR2014-002228-28-IT Italy;
Fixed dose combination Ciprofloxacin/Celecoxib
NeuroSense Therapeutics Ltd.
2019 Phase 2 NCT04165850 Israel;
2019 Phase 1 NCT04090684 United States;
Fycompa
American University of Beirut Medical Center
2019 Phase 2 NCT03377309 Lebanon;
G04CB02
Fundación Universidad Católica de Valencia San Vicente Mártir
2021 Phase 2 NCT04654689 Spain;
GA
TEVA Pharmaceutical Industries. Ltd.
2006 Phase 2 EUCTR2006-001688-49-GB Belgium;Germany;Italy;United Kingdom;
2006 - EUCTR2006-001688-49-DE Belgium;Germany;Italy;United Kingdom;
2006 - EUCTR2006-001688-49-BE Belgium;Germany;Italy;United Kingdom;
GDC-0134
Genentech, Inc.
2016 Phase 1 NCT02655614 Canada;Netherlands;United States;
GM604
Genervon Biopharmaceuticals, LLC
2013 Phase 2 NCT01854294 United States;
GSK1223249
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2012-003349-13-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
GlaxoSmithKline
2009 Phase 1 NCT00875446 France;Italy;United Kingdom;United States;
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2012-003349-13-NL Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2013 - EUCTR2012-003349-13-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 - EUCTR2012-003349-13-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
GUANA2015
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2016 Phase 2 EUCTR2014-005367-32-IT Italy;
GUANABENZ ACETATO
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2016 Phase 2 EUCTR2014-005367-32-IT Italy;
Gilenya
Massachusetts General Hospital
2013 Phase 2 NCT01786174 United States;
Gold
Peking Union Medical College Hospita
2019 - ChiCTR1900024520 China;
Gold Nanocrystals
Clene Nanomedicine
2021 Phase 2 NCT03843710 United States;
Granulocyte - colony stimulating factor (G-CSF)
University Hospital Muenster
2006 Phase 2 NCT00298597 Germany;
Granulocyte Colony Stimulating Factor
Peking University
2006 Phase 2 NCT00397423 China;
Tehran University of Medical Sciences
2012 Phase 2/Phase 3 NCT01825551 Iran, Islamic Republic of;
Growth Hormone (Somatropin)
Federico II University
2007 Phase 2 NCT00635960 Italy;
HB-adMSCs
Hope Biosciences Stem Cell Research Foundation
2020 - NCT04514952 United States;
HK-001
Everfront Biotech Co., Ltd.
2021 Phase 1 NCT03651349 Taiwan;
HUMAN ALBUMIN SOLUTION
Instituto Grifols S.A.
2014 Phase 4 EUCTR2013-004842-40-ES Spain;
HYNR-CS inj
Corestem, Inc.
2011 Phase 1/Phase 2 NCT01363401 Korea, Republic of;
HYNRCS-Allo inj
Hanyang University Seoul Hospital
2017 Phase 1 NCT03214146 Korea, Republic of;
Human Neural Stem Cells
Azienda Ospedaliera Santa Maria, Terni, Italy
2011 Phase 1 NCT01640067 Italy;
Human autologous mesenchymal stem cells
Bioinova, s.r.o.
2012 Phase 2 EUCTR2011-000362-35-CZ Czech Republic;
Huolingshengji Granules
Peking University Third Hospital
2020 Phase 2/Phase 3 NCT04950933 China;
Hyperpolarized [1-13C]pyruvate
Christoffer Laustsen
2020 Phase 2 EUCTR2020-000352-36-DK Denmark;
I-123] ADAM
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2010 - EUCTR2008-003982-21-FR France;
IC14
Implicit Bioscience
2021 Phase 2 NCT04390386 United States;
2019 Phase 2 NCT03508453 Australia;
2019 - NCT04309604 United States;
2017 Phase 1 NCT03487263 Australia;
IC14 (monoclonal antibody against human CD14)
Implicit Bioscience
2019 Phase 2 NCT03474263 Australia;United States;
IFB-088
InFlectis BioScience
2022 Phase 2 EUCTR2021-003875-32-IT France;Italy;
IL-2
Centre Hospitalier Universitaire de Nimes
2017 Phase 2 NCT03039673 France;United Kingdom;
Peking University Third Hospital
2020 Phase 2 NCT04952155 China;
IL-2 per day
Centre Hospitalier Universitaire de Nimes
2015 Phase 2 NCT02059759 France;
ILB
TikoMed AB
2018 Phase 2 NCT03613571 Sweden;
2018 Phase 2 EUCTR2017-005065-47-SE Sweden;
University of Birmingham
2019 Phase 2 NCT03705390 United Kingdom;
ILB: 100mg/ml solution for injection and infusion
University of Birmingham
2018 Phase 2 EUCTR2018-000668-28-GB United Kingdom;
IMMUNOGLOBULIN G
Annexon Biosciences
2021 Phase 2 EUCTR2021-000325-26-FR Canada;France;United States;
INTERLEUKIN-2
Nanjing Hospital Affiliated to Nanjing University of traditional Chinese Medicine
2019 Phase 0 ChiCTR2000035966 China;
ION363
IONIS PHARMACEUTICALS, INC.
- Phase 1;Phase 3 EUCTR2020-005522-28-IT Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Turkey;United Kingdom;United States;
Ionis Pharmaceuticals, Inc.
2021 Phase 3 NCT04768972 Belgium;Canada;United Kingdom;United States;
- Phase 1;Phase 2;Phase 3 EUCTR2020-005522-28-BE Belgium;Canada;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Turkey;United Kingdom;United States;
IPL344
Immunity Pharma Ltd.
2018 Phase 2 NCT03755167 Israel;
2018 Phase 1/Phase 2 NCT03652805 Israel;
ISIS 333611
Isis Pharmaceuticals
2010 Phase 1 NCT01041222 United States;
Ibudilast
MediciNova
2016 Phase 1/Phase 2 NCT02714036 United States;
Icerguastat
InFlectis BioScience
2022 Phase 2 EUCTR2021-003875-32-IT France;Italy;
Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2012-003349-13-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2012-003349-13-NL Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2013 - EUCTR2012-003349-13-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 - EUCTR2012-003349-13-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
Incobotulinum Toxin A
Beth Israel Deaconess Medical Center
2012 Phase 2 NCT01565395 United States;
Injection of salivary glands
The University of Texas Health Science Center at San Antonio
2003 Phase 2/Phase 3 NCT00125203 United States;
Inosine
Massachusetts General Hospital
2017 Phase 2 NCT03168711 United States;
2015 Phase 1 NCT02288091 United States;
Teikyo University
2017 - JPRN-UMIN000029308 Japan;
Tsukuba International Clinical Pharmacology Clinic
2016 - JPRN-UMIN000024312 Japan;
Insulin like growth factor, type 1
Mayo Clinic
2003 Phase 3 NCT00035815 Puerto Rico;United States;
Intra venous injection of stem cell
Royan Institute
2013 Phase 1 NCT01759797 Iran, Islamic Republic of;
Intrathecal autologous stem cell
Hospital Universitario Dr. Jose E. Gonzalez
2012 Phase 2/Phase 3 NCT01933321 Mexico;
Intrathecal injection
Royan Institute
2013 Phase 1 NCT01771640 Iran, Islamic Republic of;
Intravenous administration of 1 million of MSC
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
2014 Phase 1/Phase 2 NCT02290886 Spain;
Intravenous administration of 2 million of MSC
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
2014 Phase 1/Phase 2 NCT02290886 Spain;
Intravenous administration of 4 million of MSC
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
2014 Phase 1/Phase 2 NCT02290886 Spain;
Intraventricular injection
Royan Institute
2014 Phase 1 NCT01759784 Iran, Islamic Republic of;
Ioflupane 123I
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2010 - EUCTR2008-003982-21-FR France;
Iowa Oral Performance Instrument
University of Florida
2017 - NCT02962050 United States;
2016 Early Phase 1 NCT02710162 United States;
Iowa Oral Pressure Instrument
University of Florida
2016 Early Phase 1 NCT02710110 United States;
Isocaloric Diet
Fundación Universidad Católica de Valencia San Vicente Mártir
2021 Phase 2 NCT04654689 Spain;
Jevity 1.0
Massachusetts General Hospital
2009 Phase 2 NCT00983983 United States;
Jevity 1.5
Massachusetts General Hospital
2009 Phase 2 NCT00983983 United States;
KNS-760704
Knopp Biosciences
2009 Phase 2 NCT00931944 United States;
2008 Phase 2 NCT00647296 United States;
Ketanest-S
Turku University Hospital
2018 Phase 4 EUCTR2018-000142-18-FI Finland;
KetoCal
Johns Hopkins University
2009 Phase 3 NCT01016522 United States;
L-Serine
Elijah W. Stommel
2018 Phase 2 NCT03580616 United States;
Phoenix Neurological Associates, LTD
2013 Phase 1/Phase 2 NCT01835782 United States;
LAM-002A
AI Therapeutics, Inc.
2021 Phase 2 NCT05163886 United States;
LIORESAL*50CPR
AZIENDA OSPEDALIERO-UNIVERSITARIA
2010 - EUCTR2010-020257-13-IT Italy;
LITIO CARBONATO
AZIENDA OSPEDALIERA PISANA
2009 - EUCTR2009-010060-41-IT Italy;
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2009 - EUCTR2008-006224-61-ES Spain;
Lucia Galan Hospital Clinico San Carlos
2009 - EUCTR2008-005106-38-ES Spain;
Lacosamide
Chiba University
2017 Phase 1/Phase 2 NCT03186040 Japan;
Department of Neurology Chiba University Hospital
2017 - JPRN-UMIN000027476 Japan;
Kuwabara Satoshi
2017 Phase 1-2 JPRN-jRCTs031180173 Japan;
Lactose
FeGALS
2009 - JPRN-UMIN000008527 Japan;
Lamivudine
Stichting TRICALS Foundation
2021 Phase 3 EUCTR2020-005069-15-NL Australia;Netherlands;United Kingdom;
Lenograstim
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2005 - EUCTR2005-003248-75-IT Italy;
Lenzumestrocel
Corestem, Inc.
2021 Phase 3 NCT04745299 Korea, Republic of;
Leuprolide
National Center for Research Resources (NCRR)
1992 Phase 2 NCT00004771 -
Levetiracetam
Duke University
2006 Phase 2 NCT00324454 United States;
Levosimendan
Orion Corporation, Orion Pharma
2019 Phase 3 NCT03948178 Spain;
2018 Phase 3 NCT03505021 Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Lipoic acid group
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 - NCT04518540 China;
Liposomed polyphenols resveratrol and curcumin
Fundación Universidad Católica de Valencia San Vicente Mártir
2021 Phase 2 NCT04654689 Spain;
Lithium
AZIENDA OSPEDALIERA PISANA
2009 - EUCTR2009-010060-41-IT Italy;
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2008 - EUCTR2008-001094-15-IT Italy;
Assistance Publique - Hôpitaux de Paris
2009 Phase 2 NCT00925847 France;
I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX
2007 - EUCTR2007-002379-16-IT Italy;
ISTITUTO SUPERIORE DI SANITA`
2009 - EUCTR2008-006722-34-IT Italy;
Lithium Apogepha
King's College London
2009 Phase 4 EUCTR2008-006891-31-GB United Kingdom;
Lithium carbonate
Forbes Norris MDA/ALS Research Center
2008 Phase 2 NCT00790582 United States;
Lithiumcarbonaat 400 PCH tabletten
Prof. dr L.H. van den Berg, UMC-Utrecht
2008 - EUCTR2008-002110-22-NL Netherlands;
Lunasin Regimen
Richard Bedlack, M.D., Ph.D.
2016 Phase 2 NCT02709330 United States;
MANNITOLO LDB
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
2014 Phase 2 EUCTR2014-002228-28-IT Italy;
MCI-186
Mitsubishi Tanabe Pharma Corporation
2007 Phase 3 NCT00424463 Japan;
2006 Phase 3 NCT00415519 Japan;
2006 Phase 3 NCT00330681 Japan;
MCI-186 in open label phase
Mitsubishi Tanabe Pharma Corporation
2011 Phase 3 NCT01492686 Japan;
MD1003
MEDDAY PHARMACEUTICALS
2016 Phase 2 EUCTR2015-005810-31-FR France;
MedDay Pharmaceuticals SA
2016 Phase 2 NCT03114215 France;
MEMANTINE HYDROCHLORIDE
Jorge Matias-Guiu Guia
2008 - EUCTR2007-002117-39-ES Spain;
MN-166
MediciNova
2020 Phase 2/Phase 3 NCT04057898 Canada;United States;
2014 Phase 2 NCT02238626 United States;
MediciNova, Inc.
2020 Phase 2;Phase 3 EUCTR2019-003549-14-HU Germany;Greece;Hungary;Italy;Poland;Spain;United States;
MNC (Mononuclear cells)
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
2021 Phase 2 NCT04849065 Spain;
Red de Terapia Celular
2014 Phase 1 NCT02286011 Spain;
MSC-NTF cells transplantation (IM)
Brainstorm-Cell Therapeutics
2011 Phase 1/Phase 2 NCT01051882 Israel;
MSC-NTF cells transplantation (IT)
Brainstorm-Cell Therapeutics
2011 Phase 1/Phase 2 NCT01051882 Israel;
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
Brainstorm-Cell Therapeutics
2012 Phase 2 NCT01777646 Israel;
MT-1186
Mitsubishi Tanabe Development America Inc.
2021 Phase 3 EUCTR2020-000376-38-IT Canada;France;Germany;Italy;Japan;United States;
2021 Phase 3 EUCTR2019-004256-11-IT Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
2020 Phase 3 EUCTR2019-002108-41-IT Canada;France;Germany;Italy;Japan;United States;
Mitsubishi Tanabe Pharma Corporation
2020 Phase 1 NCT04254913 Japan;
2019 Phase 1 NCT04176224 Japan;
Mitsubishi Tanabe Pharma Development America, Inc.
2021 Phase 3 EUCTR2020-000376-38-DE Canada;France;Germany;Italy;Japan;United States;
2020 Phase 3 NCT04577404 Canada;France;Germany;Italy;Japan;United States;
2020 Phase 3 NCT04569084 Canada;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
2020 Phase 3 EUCTR2019-002108-41-DE Canada;France;Germany;Italy;Japan;United States;
Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
2021 Phase 3 EUCTR2019-004256-11-DE Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
MYELOSTIM 34*1FL 263MCG+1SIR
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2005 - EUCTR2005-003248-75-IT Italy;
MYONAL*30CPR RIV
AZIENDA OSPEDALIERO-UNIVERSITARIA
2010 - EUCTR2010-020257-13-IT Italy;
Masitinib (3.0)
AB Science
2013 Phase 2/Phase 3 NCT02588677 Spain;
Masitinib (4.5)
AB Science
2020 Phase 3 NCT03127267 Canada;Germany;United States;
2013 Phase 2/Phase 3 NCT02588677 Spain;
Masitinib (6.0)
AB Science
2020 Phase 3 NCT03127267 Canada;Germany;United States;
Masitinib 100 mg Tablets
AB Science
- Phase 2;Phase 3 EUCTR2010-024423-24-IE Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
Masitinib 200 mg Tablets
AB Science
- Phase 2;Phase 3 EUCTR2010-024423-24-IE Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
Masitinib mesilate
AB SCIENCE
2021 Phase 3 EUCTR2019-001862-13-IT Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
Masitinib mesylate
AB Science
2022 Phase 3 EUCTR2019-001862-13-GR Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001862-13-DK Argentina;Belgium;Canada;Denmark;France;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-PL Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2010-024423-24-IE Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
ABScience
2022 Phase 3 EUCTR2019-001862-13-PT Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001862-13-NO Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-SI Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-SE Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-ES Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-PT Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-NL Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-HU Argentina;Belgium;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-GR Argentina;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;United States;
2014 Phase 2;Phase 3 EUCTR2010-024423-24-SK Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2010-024423-24-ES France;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;
MediCabilis CBD Oil
Gold Coast Hospital and Health Service
2019 Phase 3 NCT03690791 Australia;
Medicine
Center for iPS Cell Research and Application (CiRA), Kyoto University
2019 Phase 1 JPRN-JMA-IIA00419 Japan;
Memantine
Phoenix Neurological Associates, LTD
2005 Phase 2 NCT01020331 United States;
University of Alberta
2007 Phase 2 NCT00409721 Canada;
University of Kansas Medical Center
2018 Phase 2 NCT02118727 United States;
Memantine (Ebixa)
University of Lisbon
2005 Phase 2/Phase 3 NCT00353665 Portugal;
Memantine Hydrochloride Oral Solution
University of Edinburgh
2020 Phase 2/Phase 3 NCT04302870 United Kingdom;
Mesenchymal stem cell
Alzahra Hospital, Iran
2015 Phase 1/Phase 2 NCT02116634 Iran, Islamic Republic of;
Mesenchymal stem cells
Royan Institute
2014 Phase 1 NCT02492516 Iran, Islamic Republic of;
Mesenchymal stem cells (MSC)
Hadassah Medical Organization
2016 Phase 1/Phase 2 NCT04821479 -
Mesenchymal stem cells isolated from Wharton's jelly
Polski Bank Komorek Macierzystych JSC (PBKM)
2020 Phase 1/Phase 2 NCT04651855 Poland;
Metformin
University of Florida
2020 Phase 2 NCT04220021 United States;
Methylcobalamin
University of Tokushima
2017 Phase 3 NCT03548311 Japan;
Methylphenylpyrazolone
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Methylprednisolone
Emory University
2013 Phase 2 NCT01884571 United States;
Mexiletine
Bjorn Oskarsson, MD
2013 Phase 4 NCT01811355 United States;
Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
2011 - JPRN-UMIN000006423 Japan;
University of Washington
2016 Phase 2 NCT02781454 United States;
2013 Phase 2 NCT01849770 United States;
Micro Mouth Pressure Meter
University of Florida
2016 Early Phase 1 NCT02710162 United States;
2016 Early Phase 1 NCT02710110 United States;
Midazolam
Genentech, Inc.
2016 Phase 1 NCT02655614 Canada;Netherlands;United States;
Minocycline
Columbia University
2006 Phase 2 NCT00355576 United States;
National Institute of Neurological Disorders and Stroke (NINDS)
2003 Phase 3 NCT00047723 United States;
Modal
Oregon Health and Science University
2021 - NCT04468919 United States;
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
The Methodist Hospital Research Institute
2019 Phase 2 NCT04055623 United States;
Moxifloxacin
Knopp Biosciences
2012 Phase 1 NCT01511029 United States;
Multiple Dose
Knopp Biosciences
2011 Phase 1 NCT01424163 United Kingdom;
Mycophenolate mofetil
Emory University
2013 Phase 2 NCT01884571 United States;
NP001
Neuraltus Pharmaceuticals, Inc.
2016 Phase 2 NCT02794857 Canada;United States;
2011 Phase 2 NCT01281631 United States;
2010 Phase 1 NCT01091142 United States;
Norantipyrine
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Norphenazone
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Nuedexta
Center for Neurologic Study, La Jolla, California,
2013 Phase 2 NCT01806857 United States;
NurOwn® (MSC-NTF cells)
Brainstorm-Cell Therapeutics
2017 Phase 3 NCT03280056 United States;
ODM-109
ORION CORPORATION ORION PHARMA
2019 Phase 3 EUCTR2018-004180-31-IT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-IT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Orion Corporation
2020 Phase 3 EUCTR2018-004180-31-FR Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-NL Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-IE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-GB Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-FI Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-ES Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-DE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-BE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-AT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002754-36-FR Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-NL Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-IE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-GB Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-FI Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-ES Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-BE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-AT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Orion Corporation, Orion Pharma
2015 Phase 2 NCT02487407 Germany;Ireland;Netherlands;United Kingdom;
ODM-109 capsule
Orion Corporation Orion Pharma
2015 Phase 2 EUCTR2014-004567-21-NL Germany;Ireland;Netherlands;United Kingdom;
2015 Phase 2 EUCTR2014-004567-21-IE Germany;Ireland;Netherlands;United Kingdom;
2015 Phase 2 EUCTR2014-004567-21-GB Germany;Ireland;Netherlands;United Kingdom;
2015 Phase 2 EUCTR2014-004567-21-DE Germany;Ireland;Netherlands;United Kingdom;
ONO-2506
ONO PHARMA UK LTD
2007 - EUCTR2006-002660-26-IT Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
ONO-2506PO
ONO PHARMA UK LTD
2004 - EUCTR2004-002912-27-ES Spain;
ONO Pharmaceutical Co., Ltd.
2008 Phase 2 EUCTR2007-004723-37-FR Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-GB Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-DE Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-BE Belgium;France;Germany;United Kingdom;
ONO Pharmaceutical Co.,Ltd
2007 - EUCTR2006-002660-26-NL Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2007 - EUCTR2006-002660-26-GB Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 Phase 2 EUCTR2006-002660-26-FR Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-DE Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-BE Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-AT Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
Ono Pharmaceutical Co. Ltd
2008 Phase 2 NCT00694941 Belgium;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
2006 Phase 2 NCT00403104 Austria;Belgium;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
Olanzapine
Charite University, Berlin, Germany
2011 Phase 2/Phase 3 NCT00876772 Germany;
Olesoxime
Hoffmann-La Roche
2009 Phase 3 NCT00868166 Belgium;France;Germany;Netherlands;Spain;United Kingdom;
TROPHOS
2011 - EUCTR2010-021179-10-GB Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-GB Belgium;France;Germany;Spain;United Kingdom;
TROPHOS SA
2011 Phase 2;Phase 3 EUCTR2010-021179-10-BE Belgium;Germany;Spain;United Kingdom;
2011 - EUCTR2010-021179-10-DE Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-FR Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-BE Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-007320-25-ES Belgium;France;Germany;Spain;United Kingdom;
2009 - EUCTR2008-007320-25-DE Belgium;France;Germany;Spain;United Kingdom;
Oral LEVOSIMENDAN
ORION CORPORATION ORION PHARMA
2019 Phase 3 EUCTR2018-004180-31-IT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-IT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Orion Corporation
2020 Phase 3 EUCTR2018-004180-31-FR Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-NL Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-IE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-GB Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-FI Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-ES Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-DE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-BE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-AT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002754-36-FR Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-NL Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-IE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-GB Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-FI Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-ES Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-BE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-AT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Oral nutritional supplementation
University Hospital, Limoges
2014 - NCT02152449 France;
Oxepa
Massachusetts General Hospital
2009 Phase 2 NCT00983983 United States;
Ozanezumab
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2012-003349-13-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
GlaxoSmithKline
2012 Phase 2 NCT01753076 Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2012-003349-13-NL Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2013 - EUCTR2012-003349-13-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 - EUCTR2012-003349-13-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
PARACETAMOLO
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
2014 Phase 2 EUCTR2014-002228-28-IT Italy;
PBMC autotransplantation
The First Affiliated Hospital of Dalian Medical University
2010 - NCT03085706 China;
PERFALGAN
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
2014 Phase 2 EUCTR2014-002228-28-IT Italy;
PLENUR
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2009 - EUCTR2008-006224-61-ES Spain;
Lucia Galan Hospital Clinico San Carlos
2009 - EUCTR2008-005106-38-ES Spain;
PU-AD
Samus Therapeutics, Inc.
2021 Phase 2 NCT04505358 -
Pegcetacoplam
APELLIS PHARMACEUTCIALS, INC.
2021 Phase 2 EUCTR2019-003797-10-IT Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Pegcetacoplan (APL-2)
Apellis Pharmaceuticals, Inc.
2020 Phase 2 NCT04579666 Australia;Belgium;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Perampanel
Department of Neurology, Juntendo University School of Medicine
2017 Phase 1 JPRN-UMIN000026221 Japan;
Department of Neurology, Tokyo Medical University
2017 Phase 2 JPRN-UMIN000025614 Japan;
Mayo Clinic
2018 Early Phase 1 NCT03793868 United States;
Stony Brook University
2017 - NCT03020797 United States;
Tokyo Medical University
2017 Phase 2 NCT03019419 Japan;
Phenylbutyrate
Amylyx Pharmaceuticals Inc.
2022 Phase 3 EUCTR2021-000250-26-PL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Pimozide 2 mg per day
University of Calgary
2015 Phase 2 NCT02463825 Canada;
Pimozide 2mg/day (current) or 4 mg/day (study initiation)
University of Calgary
2017 Phase 2 NCT03272503 Canada;
Pimozide 4 mg per day
University of Calgary
2015 Phase 2 NCT02463825 Canada;
Pioglitazone
University Hospital of Ulm
2008 - EUCTR2006-005410-13-DE Germany;
University of Ulm
2008 Phase 2 NCT00690118 Germany;Italy;
Pioglitazone and Tretinoin
Phoenix Neurological Associates, LTD
2008 Phase 1/Phase 2 NCT00919555 United States;
Plasma from healthy young people treatment + Riluzole
Peking University Third Hospital
2016 Early Phase 1 NCT04454840 China;
PolyMVA
University of Missouri-Columbia
2020 Phase 1 NCT04557410 United States;
PowerLung trainer
University of Florida
2016 Early Phase 1 NCT02710110 United States;
Prednisone
Emory University
2013 Phase 2 NCT01884571 United States;
Pridopidine
Merit E. Cudkowicz, MD
2020 Phase 2/Phase 3 NCT04615923 United States;
2020 Phase 2/Phase 3 NCT04297683 United States;
Probiotic
Avera McKennan Hospital & University Health Center
2017 - NCT03324399 United States;
Proleukin 18 MUI
CHU DE NIMES
2016 Phase 2 EUCTR2015-005347-14-GB United Kingdom;
Prototype capsule GDC-0134
Genentech, Inc.
2017 Phase 1 NCT03237741 United Kingdom;
Pulmonary Function Testing
University of Florida
2017 - NCT02962050 United States;
2016 Early Phase 1 NCT02710162 United States;
2016 Early Phase 1 NCT02710110 United States;
Pyrimethamine
Weill Medical College of Cornell University
2009 Phase 1/Phase 2 NCT01083667 Germany;Italy;Sweden;United States;
Q-Cells
Q Therapeutics, Inc.
2021 Phase 1/Phase 2 NCT02478450 -
R(+) pramipexole dihydrochloride monohydrate
Bennett, James P., Jr., M.D., Ph.D.
2007 Phase 1/Phase 2 NCT00600873 United States;
2005 Phase 1/Phase 2 NCT00140218 United States;
2005 - NCT00596115 -
RA15804589, C19061501-F, DNL788, DN2489, DN0002489
Sanofi-aventis recherche & développement
2022 Phase 2 EUCTR2021-004156-42-NL Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
2022 Phase 2 EUCTR2021-004156-42-ES Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
2022 Phase 2 EUCTR2021-004156-42-BE Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
RAPA-501 Autologous T cells
Rapa Therapeutics LLC
2020 Phase 1/Phase 2 NCT04220190 United States;
RAPAMUNE - 1 MG 100 COMPRESSE RIVESTITE IN BLISTER USO ORALE
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
2017 Phase 2 EUCTR2016-002399-28-IT Italy;
RILUTEK 50 mg, film-coated tablets
Aventis Pharma Ltd.
2004 - EUCTR2004-002390-23-DE Germany;
RILUZOLO
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2016 Phase 2 EUCTR2014-005367-32-IT Italy;
RNS60
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
2017 Phase 2 EUCTR2016-002382-62-IT Italy;United States;
Mario Negri Institute for Pharmacological Research
2016 Phase 2 NCT03456882 Italy;United States;
Revalesio Corporation
2022 Phase 2 NCT02988297 -
Sabrina Paganoni, M.D.
2015 Phase 1 NCT02525471 United States;
RT001
Retrotope, Inc.
2021 Phase 2 NCT04762589 Estonia;Latvia;Netherlands;Sweden;
2021 Phase 2 EUCTR2020-003962-38-SE Estonia;Netherlands;Sweden;
2021 Phase 2 EUCTR2020-003962-38-NL Estonia;Netherlands;Sweden;
2021 Phase 2 EUCTR2020-003962-38-EE Estonia;Netherlands;Sweden;
RYAH-Medtech Inhaler
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Rabeprazole
Genentech, Inc.
2017 Phase 1 NCT03237741 United Kingdom;
2016 Phase 1 NCT02655614 Canada;Netherlands;United States;
Ranolazine
University of Kansas Medical Center
2018 Phase 2 NCT03472950 United States;
Rapamycin
Azienda Ospedaliero-Universitaria di Modena
2017 Phase 2 NCT03359538 Italy;
Rasagiline
Richard Barohn, MD
2013 Phase 2 NCT01786603 United States;
University of Ulm
2013 Phase 2 NCT01879241 Germany;
Yunxia Wang, MD
2011 Phase 2 NCT01232738 Canada;United States;
Ravulizumab
Alexion Pharmaceuticals
2020 Phase 3 NCT04248465 Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Recombinant human erythropoietin(rhEPO)
Hanyang University Seoul Hospital
2016 Phase 1/Phase 2 NCT03835507 Korea, Republic of;
Reference capsule GDC-0134
Genentech, Inc.
2017 Phase 1 NCT03237741 United Kingdom;
Reldesemtiv
CYTOKINETICS, INC.
2021 Phase 3 EUCTR2020-004040-29-IT Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
Cytokinetics
2021 Phase 3 NCT04944784 Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2 NCT03160898 Australia;Canada;Ireland;Netherlands;Spain;United States;
Cytokinetics, Inc.
2018 Phase 2 EUCTR2018-000586-37-NL Australia;Canada;Ireland;Netherlands;Spain;United States;
2018 Phase 2 EUCTR2018-000586-37-IE Australia;Canada;Ireland;Netherlands;Spain;United States;
2018 Phase 2 EUCTR2018-000586-37-ES Australia;Canada;Ireland;Netherlands;Spain;United States;
Repository corticotropin injection
Mallinckrodt
2013 Phase 2 NCT01906658 United States;
Requip CR tablets
none
2018 Phase 1-2 JPRN-JMA-IIA00397 Japan;
Rilutek
Cytokinetics Inc
2013 Phase 2 EUCTR2012-004987-23-GB Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-004987-23-ES Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-IE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-DE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
- - EUCTR2012-004987-23-NL Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
Rilutek 50 mg film-coated tablets
Centre for Human Drug Research
2015 Phase 2 EUCTR2015-001431-20-NL Netherlands;
Riluzole
AB Science
2020 Phase 3 NCT03127267 Canada;Germany;United States;
2013 Phase 2/Phase 3 NCT02588677 Spain;
AZIENDA OSPEDALIERA PISANA
2009 - EUCTR2009-010060-41-IT Italy;
Aventis Pharma Ltd.
2004 - EUCTR2004-002390-23-DE Germany;
Biohaven Pharmaceuticals, Inc.
2018 - NCT03537807 -
Centre Hospitalier Universitaire de Nimes
2017 Phase 2 NCT03039673 France;United Kingdom;
Corestem, Inc.
2021 Phase 3 NCT04745299 Korea, Republic of;
Cytokinetics
2012 Phase 2 NCT01709149 Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2011 Phase 2 NCT01486849 United States;
Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
2011 - JPRN-UMIN000006423 Japan;
Guangdong Province Traditional Chinese Medical Hospital
2014 - ChiCTR-IOR-14005674 China;
Hoffmann-La Roche
2009 Phase 3 NCT00868166 Belgium;France;Germany;Netherlands;Spain;United Kingdom;
Isfahan University of Medical Sciences
2017 Phase 2/Phase 3 NCT03272802 Iran, Islamic Republic of;
Massachusetts General Hospital
2009 Phase 2/Phase 3 NCT00818389 Canada;United States;
MediciNova
2014 Phase 2 NCT02238626 United States;
Peking University Third Hospital
2021 Phase 2 ChiCTR2100044085 China;
Sanofi
2001 Phase 4 NCT00542412 Canada;
Shanghai Sixth People's Hospital
2020 Phase 0 ChiCTR2000035988 China;
University Affiliated Sixth People's Hospital
2021 Phase 0 ChiCTR2000028960 China;
University of Lisbon
2005 Phase 2/Phase 3 NCT00353665 Portugal;
University of Roma La Sapienza
2014 - NCT02645461 -
Riluzole (100 mg)
GENUV Inc.
2020 Phase 1/Phase 2 NCT04326283 Korea, Republic of;
Riluzole 50 MG (Part B)
Cytokinetics
2011 Phase 2 NCT01378676 United States;
Riluzole Oral Soluble Film
Aquestive Therapeutics
2018 Phase 2 NCT03457753 United States;
Riluzole Oral Soluble film (ROSF)
Aquestive Therapeutics
2018 Phase 2 NCT03679975 United States;
Riluzole tablet
Peking University Third Hospital
2020 Phase 2/Phase 3 NCT04950933 China;
Ritonavir
National Institute of Neurological Disorders and Stroke (NINDS)
2019 Phase 1 NCT02437110 United States;
SAR443820
Sanofi
2022 Phase 2 NCT05237284 -
Sanofi-aventis recherche & développement
2022 Phase 2 EUCTR2021-004156-42-NL Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
2022 Phase 2 EUCTR2021-004156-42-ES Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
2022 Phase 2 EUCTR2021-004156-42-BE Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
SB-509
Sangamo Biosciences
2008 Phase 2 NCT00748501 United States;
SLS-005
Merit E. Cudkowicz, MD
2022 Phase 2/Phase 3 NCT05136885 -
SLS-005 Trehalose
Merit E. Cudkowicz, MD
2020 Phase 2/Phase 3 NCT04297683 United States;
SNN0029
Newron Sweden AB
2014 Phase 1 NCT01999803 Belgium;Netherlands;
2009 Phase 1/Phase 2 NCT01384162 Belgium;
2008 Phase 1/Phase 2 NCT00800501 Belgium;
SNN0029 infusion solution
Newron Sweden AB
2015 Phase 1 NCT02269436 Belgium;Netherlands;
SODIUM PYRUVATE
Christoffer Laustsen
2020 Phase 2 EUCTR2020-000352-36-DK Denmark;
SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
Assistance Publique - Hôpitaux de Paris
2012 Phase 3 NCT01160263 France;
SUB126308
AB Science
- Phase 2;Phase 3 EUCTR2010-024423-24-IE Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
Saline solution
University of Tokushima
2017 Phase 3 NCT03548311 Japan;
Sativex
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
2011 - EUCTR2010-022808-40-IT Italy;
Scopolamine
Mie University Graduate school of medicine,Department of neurology
2013 - JPRN-UMIN000011494 Japan;
Scopolamine, atropine, edaravone and dexmedetomidine
Ruijin Hospital
2020 Phase 2 NCT04391361 China;
Selective Serotonin Uptake Inhibitors (SSRI)
St. Louis University
2015 Early Phase 1 NCT02851914 United States;
Single dose reduced
Knopp Biosciences
2011 Phase 1 NCT01424163 United Kingdom;
Single dose standard
Knopp Biosciences
2011 Phase 1 NCT01424163 United Kingdom;
Sodio phenylbutyrate
AMYLYX PHARMACEUTICALS Inc.
2021 Phase 3 EUCTR2021-000250-26-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Sodium Valproate
UMC Utrecht
2005 Phase 3 NCT00136110 Netherlands;
Sodium phenylbutyrate
Department of Veterans Affairs
2005 Phase 1/Phase 2 NCT00107770 United States;
Spirit1
Herb Spirit
2021 Phase 1 NCT02588807 Israel;
Stem Cell
Neurogen Brain and Spine Institute
2008 Phase 1 NCT02242071 India;
Stem Cells
Stem Cells Arabia
2016 Phase 1/Phase 2 NCT03067857 -
Stem cell
Neurogen Brain and Spine Institute
2008 Phase 2 NCT01984814 India;
Stem cell (HPC) implantation
Cedars-Sinai Medical Center
2017 Phase 1 NCT02943850 United States;
Stereotactic surgical device
Cedars-Sinai Medical Center
2017 Phase 1 NCT02943850 United States;
Suspension of human autologous MSC 3P in 1,5 ml
Bioinova, s.r.o.
2012 Phase 2 EUCTR2011-000362-35-CZ Czech Republic;
Suspension of human autologous MSC 3P in 1.5 ml
Bioinova, s.r.o.
2012 Phase 1/Phase 2 NCT03828123 -
Synthetic stereopure antisense oligonucleotide targeting human C9orf72 hexanucleotide repeat-containing mRNA transcripts
Wave Life Sciences UK Limited
2022 Phase 1;Phase 2 EUCTR2020-005193-94-SE Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
2022 Phase 1;Phase 2 EUCTR2020-005193-94-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
TCH346
NOVARTIS FARMA
2004 - EUCTR2004-002855-15-IT Germany;Italy;United Kingdom;
Novartis
2004 Phase 2 NCT00230074 United States;
Novartis Pharma Services AG
2004 - EUCTR2004-002855-15-GB Germany;Italy;United Kingdom;
2004 - EUCTR2004-002855-15-DE Germany;Italy;United Kingdom;
Novartis Pharmaceuticals
2003 Phase 2 NCT00072709 Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;United States;
2002 Phase 2 NCT00036413 United States;
TEVAGRASTIM
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
2014 Phase 2 EUCTR2014-002228-28-IT Italy;
TJ-68
Hiroshi Mitsumoto
2021 Phase 1/Phase 2 NCT04998305 United States;
TPN-101
Transposon Therapeutics, Inc
2022 Phase 2 EUCTR2021-002251-11-ES Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
TPN-101, 400 mg/day
Transposon Therapeutics, Inc.
2021 Phase 2 NCT04993755 France;United States;
TRO19622
Hoffmann-La Roche
2010 Phase 2/Phase 3 NCT01285583 Belgium;France;Germany;Spain;United Kingdom;
TROPHOS
2011 - EUCTR2010-021179-10-GB Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-GB Belgium;France;Germany;Spain;United Kingdom;
TROPHOS SA
2011 Phase 2;Phase 3 EUCTR2010-021179-10-BE Belgium;Germany;Spain;United Kingdom;
2011 - EUCTR2010-021179-10-DE Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-FR Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-BE Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-007320-25-ES Belgium;France;Germany;Spain;United Kingdom;
2009 - EUCTR2008-007320-25-DE Belgium;France;Germany;Spain;United Kingdom;
TUDCA
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2018-002722-22-IT Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom;
TUDCABIL
Humanitas Mirasole SpA
2019 Phase 3 EUCTR2018-002722-22-NL Belgium;Germany;Italy;Netherlands;United Kingdom;
2019 Phase 3 EUCTR2018-002722-22-DE Belgium;Germany;Italy;Netherlands;United Kingdom;
2019 Phase 3 EUCTR2018-002722-22-BE Belgium;Germany;Italy;Netherlands;United Kingdom;
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2018-002722-22-IT Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom;
TV-7110
Teva Pharmaceutical Industries, Ltd
2008 Phase 2 EUCTR2008-002062-62-FR Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 Phase 2 EUCTR2008-002062-62-ES Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-NL Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-HU Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-DE Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-BE Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Teva Pharmaceutical Industries,Ltd
2008 - EUCTR2008-002062-62-IT Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Tacrolimus
Emory University
2013 Phase 2 NCT01884571 United States;
Talampanel
Teva Pharmaceutical Industries
2009 Phase 2 NCT00982150 Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States;
2008 Phase 2 NCT00696332 Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States;
Teva Pharmaceutical Industries, Ltd
2008 Phase 2 EUCTR2008-002062-62-FR Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 Phase 2 EUCTR2008-002062-62-ES Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-NL Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-HU Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-DE Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-BE Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Teva Pharmaceutical Industries,Ltd
2008 - EUCTR2008-002062-62-IT Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Tallampanel
Teva Pharmaceutical Industries,Ltd
2008 - EUCTR2008-002062-62-IT Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Tamoxifen
Nazem Atassi
2011 Phase 2 NCT01257581 United States;
University of Wisconsin, Madison
2001 Phase 2 NCT00214110 United States;
Tamoxifen 40 mg daily for one year
Taipei Medical University Shuang Ho Hospital
2014 Phase 1/Phase 2 NCT02166944 Taiwan;
Taurolite
IRCCS ISTITUTO CLINICO HUMANITAS
2019 Phase 3 EUCTR2018-002722-22-GB Netherlands;United Kingdom;
Tauroursodeoxycholic acid
IRCCS ISTITUTO CLINICO HUMANITAS
2019 Phase 3 EUCTR2018-002722-22-GB Netherlands;United Kingdom;
ISTITUTO NEUROLOGICO CARLO BESTA
2008 - EUCTR2007-001592-10-IT Italy;
Tauroursodeoxycholic acid (TUDCA)
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
2008 Phase 2 NCT00877604 Italy;
Taurursodiol
Amylyx Pharmaceuticals Inc.
2022 Phase 3 EUCTR2021-000250-26-PL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-SE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Tenofovir alafenamide (TAF)
National Institute of Neurological Disorders and Stroke (NINDS)
2019 Phase 1 NCT02437110 United States;
Testosterone
National Center for Research Resources (NCRR)
1992 Phase 2 NCT00004771 -
Thalidomide
Dartmouth-Hitchcock Medical Center
2005 Phase 2 NCT00140452 United States;
Thalidomide (drug)
Charite University, Berlin, Germany
2005 Phase 2 NCT00231140 Germany;
Theracurmin HP
Richard Bedlack, M.D., Ph.D.
2020 Phase 2 NCT04499963 United States;
Tioctic acid
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2006 - EUCTR2005-005152-40-IT Italy;
Tirasemtiv
CYTOKINETICS, INC.
2016 Phase 3 EUCTR2014-005413-23-IT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Cytokinetics
2016 Phase 3 NCT02936635 Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 NCT02496767 Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Cytokinetics Inc
2013 Phase 2 EUCTR2012-004987-23-GB Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-004987-23-ES Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-IE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-DE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
- - EUCTR2012-004987-23-NL Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
Cytokinetics, Inc.
2017 Phase 3 EUCTR2016-002629-13-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-FR Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-ES Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-ES Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-DE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005413-23-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Tocilizumab
Barrow Neurological Institute
2015 Phase 2 NCT02469896 United States;
Tocotrienols
University of Malaya
2019 Phase 2 NCT04140136 Malaysia;
Tofersen
BIOGEN IDEC RESEARCH LIMITED
2022 Phase 3 EUCTR2020-004590-51-IT Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Biogen Idec Research Limited
2021 Phase 3 EUCTR2020-004590-51-FR Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004590-51-ES Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004590-51-DE Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2016-003225-41-ES Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2016-003225-41-DK Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2020 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-DK Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003225-41-DE Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003225-41-BE Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-DE Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
Trametinib (0.5 mg)
GENUV Inc.
2020 Phase 1/Phase 2 NCT04326283 Korea, Republic of;
Trametinib (1 mg)
GENUV Inc.
2020 Phase 1/Phase 2 NCT04326283 Korea, Republic of;
Trametinib (2 mg)
GENUV Inc.
2020 Phase 1/Phase 2 NCT04326283 Korea, Republic of;
Trazodone Hydrochloride oral solution
University of Edinburgh
2020 Phase 2/Phase 3 NCT04302870 United Kingdom;
Tretinoin and Pioglitazone HCL
Phoenix Neurological Associates, LTD
2008 Phase 1/Phase 2 NCT00919555 United States;
Tricyclic Antidepressants (TCA)
St. Louis University
2015 Early Phase 1 NCT02851914 United States;
Triheptanoin
Richard Bedlack, M.D., Ph.D.
2018 Phase 1/Phase 2 NCT03506425 United States;
Trimetazidine
The University of Queensland
2021 Phase 2 EUCTR2020-005018-17-NL Australia;Netherlands;
Trimetazidine Dihydrochloride
The University of Queensland
2021 Phase 2 NCT04788745 Australia;Netherlands;United Kingdom;
Triumeq
Neuroscience Trials Australia
2016 Phase 2 NCT02868580 Australia;
Stichting TRICALS Foundation
2021 Phase 3 EUCTR2020-005069-15-NL Australia;Netherlands;United Kingdom;
Trobalt
Centre for Human Drug Research
2015 Phase 2 EUCTR2015-001431-20-NL Netherlands;
Téralithe LP
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-003707-32-FR France;
Ultomiris
ALEXION PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2019-004619-30-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Alexion Pharmaceuticals
2020 Phase 3 EUCTR2019-004619-30-SE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Ultra-high-caloric carbohydrate-rich diet
Albert Christian Ludolph, Prof.
2019 Phase 1 NCT04172792 Germany;
Ultra-high-caloric fatty diet
Albert Christian Ludolph, Prof.
2019 Phase 1 NCT04172792 Germany;
Umbilical cord blood therapy
MinYoung Kim, M.D.
2014 - NCT02236065 Korea, Republic of;
Ursodoxicoltaurina
Amylyx Pharmaceuticals Inc.
2021 Phase 3 EUCTR2021-000250-26-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Ursodoxicoltaurine
Amylyx Pharmaceuticals Inc.
2022 Phase 3 EUCTR2021-000250-26-PL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-SE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
VM202
Helixmith Co., Ltd.
2014 Phase 1/Phase 2 NCT02039401 United States;
Vastarel
The University of Queensland
2021 Phase 2 EUCTR2020-005018-17-NL Australia;Netherlands;
Verdiperstat
Merit E. Cudkowicz, MD
2020 Phase 2/Phase 3 NCT04436510 United States;
2020 Phase 2/Phase 3 NCT04297683 United States;
Videofluoroscopic Swallowing Study
University of Florida
2016 Early Phase 1 NCT02710162 United States;
Videofluoroscopic Swallowing Study (VFSS)
University of Florida
2017 - NCT02962050 United States;
Videofluoroscopic swallowing study
University of Florida
2016 Early Phase 1 NCT02710110 United States;
Vitamin E
Lawson Health Research Institute
2006 Phase 3 NCT00372879 Canada;
Voluntary Peak Cough Flow Testing
University of Florida
2017 - NCT02962050 United States;
WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELLS
Polski Bank Komórek Macierzystych JSC (PBKM)
2020 Phase 1;Phase 2 EUCTR2018-004171-12-PL Poland;
WVE-004
Wave Life Sciences Ltd.
2021 Phase 1/Phase 2 NCT04931862 Australia;Canada;Ireland;Netherlands;United Kingdom;
Wave Life Sciences UK Limited
2022 Phase 1;Phase 2 EUCTR2020-005193-94-SE Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
2022 Phase 1;Phase 2 EUCTR2020-005193-94-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
Water
Clinical Research Hospital Tokyo
2014 - JPRN-UMIN000015054 Japan;
National Hospital Organization Takasaki General Medical Center
2015 - JPRN-UMIN000019111 Japan;
Withania somnifera
Sunnybrook Health Sciences Centre
2021 Phase 2 NCT05031351 -
YAM80
Yoshino Neurology Clinic
2009 Phase 2 NCT00886977 Japan;
ZIBREN*20BUST
IST. DI RICERCHE FARMACOLOG. M. NEGRI
2005 - EUCTR2004-004158-23-IT Italy;
Zilucoplan
Merit E. Cudkowicz, MD
2020 Phase 2/Phase 3 NCT04436497 United States;
2020 Phase 2/Phase 3 NCT04297683 United States;
Zinc and Copper
Phoenix Neurological Associates, LTD
2010 Phase 1/Phase 2 NCT01259050 United States;
Zyprexa
Charité – Universitätsmedizin Berlin
2008 - EUCTR2007-003775-39-DE Germany;
[11C]CPPC Injection
Johns Hopkins University
2021 Phase 1 NCT04749433 United States;
[11C]MPC6827
Columbia University
2021 Early Phase 1 NCT04575727 United States;
[18F] GE-180
Massachusetts General Hospital
2015 - NCT02559869 United States;
[18F]DPA-714 PET
University Hospital, Tours
2015 Early Phase 1 NCT02405403 France;
[18F]PBR06
Molecular NeuroImaging
2016 Phase 1 NCT03876002 United States;
glatiramer acetate
TEVA Pharmaceutical Industries. Ltd.
2006 Phase 2 EUCTR2006-001688-49-GB Belgium;Germany;Italy;United Kingdom;
2006 - EUCTR2006-001688-49-DE Belgium;Germany;Italy;United Kingdom;
2006 - EUCTR2006-001688-49-BE Belgium;Germany;Italy;United Kingdom;
Teva Pharmaceutical Industries, Ltd.
2006 Phase 2 NCT00326625 Belgium;France;Germany;Israel;Italy;United Kingdom;
glucose water solution
Centre Hospitalier Universitaire de Nimes
2017 Phase 2 NCT03039673 France;United Kingdom;
ONO Pharmaceutical Co., Ltd.
2008 Phase 2 EUCTR2007-004723-37-FR Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-GB Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-DE Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-BE Belgium;France;Germany;United Kingdom;
ONO Pharmaceutical Co.,Ltd
2007 - EUCTR2006-002660-26-NL Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2007 - EUCTR2006-002660-26-GB Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 Phase 2 EUCTR2006-002660-26-FR Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-DE Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-BE Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-AT Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
(6R)-4, 5, 6, 7 - tetrahydro-N6-propyl-2,6-benzothiazolidiamine dihydrochloride monohydrate
Biogen Idec Limited
2011 Phase 3 EUCTR2010-022818-19-ES Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;
(R)-(-)-2-Propyloctaroic acid
ONO PHARMA UK LTD
2004 - EUCTR2004-002912-27-ES Spain;
201600930
The University of Queensland
2021 Phase 2 EUCTR2020-005018-17-NL Australia;Netherlands;
3-methyl-1-phenyl-4, 5-dihydro-1H-pyrazol-5-one.
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
3K3A-APC Protein
Macquarie University, Australia
2021 Phase 2 NCT05039268 Australia;
4 cholesten-3-one, oxime
TROPHOS
2011 - EUCTR2010-021179-10-GB Germany;Spain;United Kingdom;
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-thiazolyl]amino]phenyl]-benzamide, methane sulphonic acid salt. AB1010base
AB SCIENCE
2021 Phase 3 EUCTR2019-001862-13-IT Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
4-cholesten-3-one, oxime
TROPHOS
2009 Phase 2;Phase 3 EUCTR2008-007320-25-GB Belgium;France;Germany;Spain;United Kingdom;
TROPHOS SA
2011 Phase 2;Phase 3 EUCTR2010-021179-10-BE Belgium;Germany;Spain;United Kingdom;
2011 - EUCTR2010-021179-10-DE Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-FR Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-BE Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-007320-25-ES Belgium;France;Germany;Spain;United Kingdom;
2009 - EUCTR2008-007320-25-DE Belgium;France;Germany;Spain;United Kingdom;
6-ethynyl-1-(pentan-3-yl)-1H-imidazo[4,5-b]pyrazin-2(3H)-one
CYTOKINETICS, INC.
2016 Phase 3 EUCTR2014-005413-23-IT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Cytokinetics Inc
2013 Phase 2 EUCTR2012-004987-23-GB Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-004987-23-ES Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-IE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-DE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
- - EUCTR2012-004987-23-NL Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
Cytokinetics, Inc.
2017 Phase 3 EUCTR2016-002629-13-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-FR Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-ES Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-ES Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-DE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005413-23-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
9-CIS, 12-CIS-11,11-D2-LINOLEIC ACID ETHYL ESTER
Retrotope, Inc.
2021 Phase 2 EUCTR2020-003962-38-SE Estonia;Netherlands;Sweden;
2021 Phase 2 EUCTR2020-003962-38-NL Estonia;Netherlands;Sweden;
2021 Phase 2 EUCTR2020-003962-38-EE Estonia;Netherlands;Sweden;
AB 1003
AB SCIENCE
2021 Phase 3 EUCTR2019-001862-13-IT Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
AB1010
AB SCIENCE
2021 Phase 3 EUCTR2019-001862-13-IT Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2015 - EUCTR2010-024423-24-IT Argentina;Colombia;France;Germany;Greece;Hungary;Italy;Mexico;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;
AB Science
2022 Phase 3 EUCTR2019-001862-13-GR Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001862-13-DK Argentina;Belgium;Canada;Denmark;France;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-PL Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2019-001862-13-IE Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2019-001862-13-GB Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2010-024423-24-IE Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
ABScience
2022 Phase 3 EUCTR2019-001862-13-PT Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001862-13-NO Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-SI Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-SE Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-ES Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-PT Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-NL Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-HU Argentina;Belgium;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-GR Argentina;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;United States;
2014 Phase 2;Phase 3 EUCTR2010-024423-24-SK Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2010-024423-24-ES France;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;
ABBV-CLS-7262
Calico Life Sciences LLC
2021 Phase 1 NCT04948645 Canada;United States;
ACIDO TAUROURSODESOSSICOLICO
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2018-002722-22-IT Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom;
AL001
Alector Inc.
2021 Phase 2 NCT05053035 United States;
ALPHA-LIPOIC ACID
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2006 - EUCTR2005-005152-40-IT Italy;
ALXN1210
ALEXION PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2019-004619-30-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Alexion Pharmaceuticals
2020 Phase 3 EUCTR2019-004619-30-SE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
ALZT-OP1a (cromolyn)
AZTherapies, Inc.
2020 Phase 2 NCT04428775 United States;
AMSC
Bioinova, s.r.o.
2012 Phase 2 EUCTR2011-000362-35-CZ Czech Republic;
AMX0035
AMYLYX PHARMACEUTICALS Inc.
2021 Phase 3 EUCTR2021-000250-26-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Amylyx Pharmaceuticals Inc.
2022 Phase 3 EUCTR2021-000250-26-PL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2022 - NCT05286372 -
2021 Phase 3 NCT05021536 Puerto Rico;United States;
2021 Phase 3 EUCTR2021-000250-26-SE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2020 Phase 2/Phase 3 NCT04516096 United States;
2018 Phase 2 NCT03488524 United States;
2017 Phase 2/Phase 3 NCT03127514 United States;
ANX005
Annexon Biosciences
2021 Phase 2 EUCTR2021-000325-26-FR Canada;France;United States;
Annexon, Inc.
2021 Phase 2 NCT04569435 Canada;France;United States;
AP-101
AL-S Pharma
2021 Phase 2 NCT05039099 Canada;Germany;Korea, Republic of;Sweden;United States;
2019 Phase 1 NCT03981536 Canada;
APL-2
APELLIS PHARMACEUTCIALS, INC.
2021 Phase 2 EUCTR2019-003797-10-IT Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Apellis Pharmaceuticals, Inc.
2021 Phase 2 EUCTR2019-003797-10-NL Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2019-003797-10-IE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2019-003797-10-DE Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2019-003797-10-CZ Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
APO-P001
Apodemus AB
2014 Phase 2 EUCTR2012-002099-15-SE Sweden;
AT-1501
Anelixis Therapeutics, LLC
2020 Phase 2 NCT04322149 Canada;United States;
AVP-923
Avanir Pharmaceuticals
2001 Phase 3 NCT00021697 United States;
AZILECT® 1 mg Tabletten
Universitätsklinikum Ulm
2013 Phase 2 EUCTR2011-004482-32-DE Germany;
Abacavir
Stichting TRICALS Foundation
2021 Phase 3 EUCTR2020-005069-15-NL Australia;Netherlands;United Kingdom;
Acetylcarnitine
IST. DI RICERCHE FARMACOLOG. M. NEGRI
2005 - EUCTR2004-004158-23-IT Italy;
Acthar
Mallinckrodt
2017 Phase 2/Phase 3 NCT03068754 Argentina;Canada;Chile;Colombia;Mexico;Peru;United States;
Actos
University Hospital of Ulm
2008 - EUCTR2006-005410-13-DE Germany;
Albumin
Instituto Grifols, S.A.
2014 Phase 2 NCT02479802 Spain;
Albutein
Grifols Therapeutics LLC
2016 Phase 2 NCT02872142 United States;
Instituto Grifols S.A.
2014 Phase 4 EUCTR2013-004842-40-ES Spain;
Albúmina humana
Instituto Grifols S.A.
2014 Phase 4 EUCTR2013-004842-40-ES Spain;
All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-P-thioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidine
Ionis Pharmaceuticals, Inc.
- Phase 1;Phase 2;Phase 3 EUCTR2020-005522-28-BE Belgium;Canada;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Turkey;United Kingdom;United States;
All-P-ambo-2'-O-(2-methoxyethyl)-P-thioguanylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methylcytidylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)adenylyl-(3'-O->5'-O)-2'-O-(2-methoxyethyl)-5-methyluridylyl-(3'-O->5'-O)-2'-deoxy-P-thioguanylyl-(3'-O->5'-O)-P-thiothymidylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-Pthioadenylyl-(3'-O->5'-O)-2'-deoxy-5-methyl-P-thiocytidylyl-(3'-O->5'-O)-2'-deoxy-
IONIS PHARMACEUTICALS, INC.
- Phase 1;Phase 3 EUCTR2020-005522-28-IT Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Turkey;United Kingdom;United States;
AlloRx
The Foundation for Orthopaedics and Regenerative Medicine
2022 Phase 1 NCT05003921 Antigua and Barbuda;
Amivita
Wujin People's Hospital
2017 - NCT03103815 China;
Anakinra
Charite University, Berlin, Germany
2011 Phase 2 NCT01277315 Germany;
Arimoclomol
CytRx
2008 Phase 2 NCT00561366 Canada;United States;
2005 Phase 2 NCT00244244 United States;
Orphazyme
2019 Phase 3 NCT03836716 Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 NCT03491462 Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
University of Miami
2009 Phase 2/Phase 3 NCT00706147 United States;
AstroRx
Kadimastem
2018 Phase 1/Phase 2 NCT03482050 Israel;
Autologous Adipose-derived Mesenchymal Stromal Cells
Mayo Clinic
2017 Phase 2 NCT03268603 United States;
Autologous MSC-NTF cells
Brainstorm-Cell Therapeutics
2014 Phase 2 NCT02017912 United States;
Autologous Mesenchymal stem cells (MSCs)
Hospital e Maternidade Dr. Christóvão da Gama
2015 Phase 1 NCT02987413 Brazil;
Autologous T-regulatory lymphocytes
Stanley H. Appel, MD
2016 Phase 1 NCT03241784 United States;
Autologous adult bone marrow mononuclear cells (BM-MNC) unexpanded
Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
2019 Phase 2 EUCTR2019-002302-46-ES Spain;
Autologous adult bone marrow mononuclear cells unexpanded
Fundación para la Formación e Investigación Sanitarias de la Región de Murcia
2019 Phase 2 EUCTR2019-002302-46-ES Spain;
Autologous bone marrow mononucleated cells
Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)
2014 - EUCTR2011-004801-25-ES Spain;
Autologous bone marrow-derived stem cells
TCA Cellular Therapy
2010 Phase 1 NCT01082653 United States;
Autologous mesenchymal stem cells
Mayo Clinic
2012 Phase 1 NCT01609283 United States;
2010 Phase 1 NCT01142856 United States;
BHV-0223
Biohaven Pharmaceuticals, Inc.
2018 Phase 1 NCT03520517 United States;
BIIB050 / KNS-760704
Biogen Idec Limited
2011 Phase 3 EUCTR2010-022818-19-ES Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;
2011 Phase 3 EUCTR2010-022818-19-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-SE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-NL Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-IE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-GB Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-DE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
BIIB050/KNS-760704
Biogen Idec Research Limited
2012 Phase 3 EUCTR2011-006119-70-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-SE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-NL Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-IE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-GB Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-ES Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-DE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
BIIB067
Biogen
2017 Phase 3 NCT03070119 Belgium;Canada;France;Germany;Italy;Japan;New Zealand;United Kingdom;United States;
2016 Phase 3 NCT02623699 Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Sweden;United Kingdom;United States;
BIIB067 (ISIS666853)
BIOGEN IDEC RESEARCH LIMITED
2022 Phase 3 EUCTR2020-004590-51-IT Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2016-003225-41-IT Australia;Belgium;Canada;Denmark;European Union;Germany;Italy;Japan;Poland;Spain;United Kingdom;United States;
Biogen Idec Research Limited
2021 Phase 3 EUCTR2020-004590-51-FR Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004590-51-ES Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004590-51-DE Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2016-003225-41-ES Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2016-003225-41-PL Argentina;Australia;Belgium;Canada;Denmark;European Union;Germany;Japan;Korea, Republic of;Poland;United Kingdom;United States;
2020 Phase 3 EUCTR2016-003225-41-DK Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2015-004098-33-PL Argentina;Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Poland;Sweden;United Kingdom;United States;
2020 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-DK Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003225-41-DE Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003225-41-BE Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2017 Phase 1;Phase 3 EUCTR2016-003225-41-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-SE Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-GB Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-DE Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
2016 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-BE Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
BIIB067 (Tofersen)
Biogen
2021 Phase 3 NCT04856982 Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
BIIB078
Biogen
2020 Phase 1 NCT04288856 Canada;Netherlands;Switzerland;United Kingdom;United States;
2018 Phase 1 NCT03626012 Canada;Ireland;Netherlands;Switzerland;United Kingdom;United States;
BIIB100
Biogen
2019 Phase 1 NCT03945279 United States;
BIIB105
Biogen
2020 Phase 1 NCT04494256 Canada;Italy;Netherlands;United States;
BLZ945
Novartis Pharma AG
2019 Phase 2 EUCTR2019-000826-22-SE Finland;Sweden;United States;
2019 Phase 2 EUCTR2019-000826-22-FI Finland;Sweden;United States;
Novartis Pharmaceuticals
2019 Phase 2 NCT04066244 Finland;Sweden;United States;
BOTOX 100 UNITES ALLERGAN (PR1)
Hospices Civils de Lyon
2011 Phase 2 EUCTR2010-023161-21-FR France;
BRX-345
ORPHAZYME APS
2019 Phase 3 EUCTR2019-000374-39-IT Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-IT Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Orphazyme A/S
2019 Phase 3 EUCTR2019-000374-39-SE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000374-39-PL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000374-39-NL Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000374-39-GB Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000374-39-ES Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000374-39-DE Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-SE Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-PL Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-NL Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-GB Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-FR Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-ES Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2018 Phase 3 EUCTR2018-000137-13-BE Belgium;Canada;France;Germany;Italy;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Baclofen
AZIENDA OSPEDALIERO-UNIVERSITARIA
2010 - EUCTR2010-020257-13-IT Italy;
Barium
Milton S. Hershey Medical Center
2022 - NCT04889898 United States;
Basiliximab
Emory University
2013 Phase 2 NCT01884571 United States;
Beta Hydroxybutyrate
University of Ulm
2021 Phase 2 NCT04820478 Germany;
Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days
Edward Kasaraskis
2017 Early Phase 1 NCT03707795 United States;
Biotin
American University of Beirut Medical Center
2018 Phase 2 NCT03427086 Lebanon;
Blood sample and environmental survey
Centre Hospitalier Universitaire de Pointe-a-Pitre
2014 - NCT03367650 Guadeloupe;Martinique;
Bosutinib
Center for iPS Cell Research and Application, Kyoto University
2019 Phase 1 JPRN-UMIN000036295 Japan;
Inoue Haruhisa
2019 Phase 1 JPRN-jRCT2051190001 Japan;
Kyoto University
2019 Phase 1 NCT04744532 Japan;
Botox injection
Hospices Civils de Lyon
2012 Phase 2 NCT01551940 France;
Botulinum toxin type B (Myobloc)
The University of Texas Health Science Center at San Antonio
2003 Phase 2/Phase 3 NCT00125203 United States;
Butylphthalide
Peking Union Medical College Hospital
2015 - ChiCTR-IPR-15007365 China;
CARBOLITHIUM
I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX
2007 - EUCTR2007-002379-16-IT Italy;
ISTITUTO SUPERIORE DI SANITA`
2009 - EUCTR2008-006722-34-IT Italy;
CARBOLITHIUM*100CPS
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2008 - EUCTR2008-001094-15-IT Italy;
CC100
Chemigen, LLC
2017 Phase 1 NCT03049046 United States;
CK-2017357
CYTOKINETICS, INC.
2016 Phase 3 EUCTR2014-005413-23-IT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Cytokinetics
2012 Phase 2 NCT01709149 Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2011 Phase 2 NCT01486849 United States;
2010 Phase 2 NCT01089010 United States;
Cytokinetics, Inc.
2017 Phase 3 EUCTR2016-002629-13-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-FR Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-ES Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-ES Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-DE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005413-23-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
CK-2017357 (Part A)
Cytokinetics
2011 Phase 2 NCT01378676 United States;
CK-2017357 (Part B)
Cytokinetics
2011 Phase 2 NCT01378676 United States;
CK-2127107
CYTOKINETICS, INC.
2021 Phase 3 EUCTR2020-004040-29-IT Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
Cytokinetics Inc
2022 Phase 3 EUCTR2020-004040-29-PT Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004040-29-SE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004040-29-NL Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004040-29-IE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004040-29-ES Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004040-29-FR Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004040-29-DE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
- Phase 3 EUCTR2020-004040-29-BE Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
Cytokinetics, Inc.
2018 Phase 2 EUCTR2018-000586-37-NL Australia;Canada;Ireland;Netherlands;Spain;United States;
2018 Phase 2 EUCTR2018-000586-37-IE Australia;Canada;Ireland;Netherlands;Spain;United States;
2018 Phase 2 EUCTR2018-000586-37-ES Australia;Canada;Ireland;Netherlands;Spain;United States;
CK2017357
Cytokinetics Inc
2013 Phase 2 EUCTR2012-004987-23-GB Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-004987-23-ES Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-IE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-DE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
- - EUCTR2012-004987-23-NL Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
CNM-Au8
Clene Nanomedicine
2022 - NCT05281484 United States;
2019 Phase 2 NCT04098406 Australia;
2019 - NCT04081714 United States;
Merit E. Cudkowicz, MD
2020 Phase 2/Phase 3 NCT04414345 United States;
2020 Phase 2/Phase 3 NCT04297683 United States;
COLCHICINA LIRCA - 1 MG COMPRESSE 60 COMPRESSE
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
2018 Phase 2 EUCTR2017-004459-21-IT Italy;
Caffeine
Genentech, Inc.
2016 Phase 1 NCT02655614 Canada;Netherlands;United States;
Calogen
University of Ulm
2015 - NCT02306590 Germany;
Cannabis Sativa extract Oromucosal spray
Ospedale San Raffaele
2013 Phase 2/Phase 3 NCT01776970 Italy;
Cannabis, Medical
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Capsaicin
University of Florida
2016 Early Phase 1 NCT02710162 United States;
2016 Early Phase 1 NCT02710110 United States;
Capsaicin Challenge
University of Florida
2017 - NCT02962050 United States;
Carbidopa-levodopa
Washington University School of Medicine
2019 Phase 1 NCT03929068 United States;
Carbonate de lithium
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-003707-32-FR France;
Ceftriaxone
AZIENDA OSPEDALIERA PISANA
2007 - EUCTR2007-004165-17-IT Italy;
Massachusetts General Hospital
2006 Phase 3 NCT00349622 Canada;Puerto Rico;United States;
Celecoxib
Columbia University
2006 Phase 2 NCT00355576 United States;
Cell-based therapeutics
Pomeranian Medical University Szczecin
2010 Phase 1 NCT02193893 Poland;
Cell-based therapy
University of Warmia and Mazury
2015 Phase 1 NCT02881489 -
2015 Phase 1 NCT02881476 -
Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients
Mossakowski Medical Research Centre Polish Academy of Sciences
2015 Phase 1 NCT03296501 Poland;
Cimetidine plus Dexpramipexole
Knopp Biosciences
2012 Phase 1 NCT01536249 United States;
Cistanche Total Glycosides
Peking University
2008 Phase 2 NCT00753571 China;
Clenbuterol
Dwight Koeberl, M.D., Ph.D.
2020 Phase 2 NCT04245709 United States;
Coenzyme Q10
Columbia University
2005 Phase 2 NCT00243932 United States;
Colchicine 1 MG Oral Tablet
Azienda Ospedaliero-Universitaria di Modena
2019 Phase 2 NCT03693781 Italy;
Combination Product: Active treatment with dual therapy
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
2016 Phase 2 NCT03204500 Mexico;
Control group
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 - NCT04518540 China;
Copegus
Apodemus AB
2014 Phase 2 EUCTR2012-002099-15-SE Sweden;
Creatine
Columbia University
2006 Phase 2 NCT00355576 United States;
National Center for Research Resources (NCRR)
2000 Phase 2 NCT00005674 United States;
Nazem Atassi
2011 Phase 2 NCT01257581 United States;
Creatine Monohydrate
The Avicena Group
2003 Phase 3 NCT00069186 United States;
Creatine monohydrate
National Center for Complementary and Integrative Health (NCCIH)
2002 Phase 2 NCT00070993 United States;
Creatinine
National Center for Research Resources (NCRR)
2000 Phase 2 NCT00005766 United States;
Cu(II)ATSM
Collaborative Medicinal Development Pty Limited
2020 Phase 2 NCT04313166 Australia;
2019 Phase 2/Phase 3 NCT04082832 Australia;
2018 Phase 1/Phase 2 NCT03136809 Australia;
2016 Phase 1 NCT02870634 Australia;
Células Mesenquimales de tejido adiposo
FUNDACIÓN PROGRESO Y SALUD
2013 - EUCTR2011-006254-85-ES Spain;
Células madre mesenquimales de tejido adiposo autólogo
FUNDACIÓN PROGRESO Y SALUD
2013 - EUCTR2011-006254-85-ES Spain;
Células troncales hematopoyéticas autólogas adultas extraidas de médula ósea
Fundación Sanitaria para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO)
2014 - EUCTR2011-004801-25-ES Spain;
DEXTRAN SULFATE SODIUM
TikoMed AB
2018 Phase 2 EUCTR2017-005065-47-SE Sweden;
DNL343
Denali Therapeutics Inc.
2021 Phase 1 NCT05006352 Netherlands;United States;
DNL747
Sanofi
2018 Phase 1 NCT03757351 Netherlands;United States;
Daraprim
Weill Medical College of Cornell University
2013 - EUCTR2011-004798-99-DE Germany;Italy;United States;
Darunavir
National Institute of Neurological Disorders and Stroke (NINDS)
2019 Phase 1 NCT02437110 United States;
Deferiprone
University Hospital, Lille
2019 Phase 2/Phase 3 NCT03293069 France;
2013 Phase 2 NCT02164253 France;
2011 - NCT02880033 France;
Deferiprone DR
centre hospitalier universitaire de Lille
2018 Phase 3 EUCTR2017-003763-35-FR France;
Dexdor
Turku University Hospital
2018 Phase 4 EUCTR2018-000142-18-FI Finland;
Dexpramipexole
Biogen Idec Limited
2011 Phase 3 EUCTR2010-022818-19-ES Belgium;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;
Biogen Idec Research Limited
2012 Phase 3 EUCTR2011-006119-70-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-SE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-NL Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-IE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-GB Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-ES Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 - EUCTR2011-006119-70-DE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
Knopp Biosciences
2012 Phase 3 NCT01622088 Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2012 Phase 1 NCT01511029 United States;
2011 Phase 3 NCT01281189 Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 Phase 1 NCT01449578 United States;
Dexpramipexole (dose 1)
Knopp Biosciences
2011 Phase 1 NCT01424176 United States;
Dexpramipexole (dose 2)
Knopp Biosciences
2011 Phase 1 NCT01424176 United States;
Dexpramipexole Dichydrochloride
Biogen Idec Limited
2011 Phase 3 EUCTR2010-022818-19-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-SE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-NL Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-IE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
2011 - EUCTR2010-022818-19-GB Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
Dexpramipexole Dihydrochloride
Biogen Idec Limited
2011 - EUCTR2010-022818-19-DE Australia;Canada;Germany;Ireland;Netherlands;Spain;Sweden;United Kingdom;United States;
Dextran Sodium Sulfur Salt 5, Mw 5 kDa. a type of Low Molecular Weight Dextran Sulfate (LMW-DS)
University of Birmingham
2018 Phase 2 EUCTR2018-000668-28-GB United Kingdom;
Dextromethorphan HBr and quinidine sulfate
University of Florida
2019 Phase 1/Phase 2 NCT03883581 United States;
Dextromethorphan hydrobromide 20 mg and quinidine sulfate
Avanir Pharmaceuticals
2007 Phase 3 NCT00573443 Argentina;Brazil;United States;
Dextromethorphan hydrobromide 30 mg and quinidine sulfate
Avanir Pharmaceuticals
2007 Phase 3 NCT00573443 Argentina;Brazil;United States;
Digital recording of speech and swallow sounds using the Beiwe Digital Health App on a personal smartphone
Milton S. Hershey Medical Center
2022 - NCT04889898 United States;
Dolutegravir
National Institute of Neurological Disorders and Stroke (NINDS)
2019 Phase 1 NCT02437110 United States;
Stichting TRICALS Foundation
2021 Phase 3 EUCTR2020-005069-15-NL Australia;Netherlands;United Kingdom;
Dronabinol
Cantonal Hospital of St. Gallen
2005 - NCT00812851 Switzerland;
Dutasterida
Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia
2021 Phase 2 EUCTR2021-001989-38-ES Spain;
E0302 (mecobalamin)
Eisai Co., Ltd.
2008 Phase 2/Phase 3 NCT00445172 Japan;
2007 Phase 2/Phase 3 NCT00444613 Japan;
EBIXA
Jorge Matias-Guiu Guia
2008 - EUCTR2007-002117-39-ES Spain;
EH301 (Nicotinamide Riboside/Pterostilbene)
Haukeland University Hospital
2020 - NCT04562831 Norway;
EPI-589
Fujita Koji
2021 Phase 2 JPRN-jRCT2061210031 Japan;
Hamatani Tatsuto
2021 Phase 1 JPRN-jRCT2071210023 Japan;
2018 Phase 1 JPRN-jRCT2071210022 Japan;
PTC Therapeutics
2016 Phase 2 NCT02460679 United States;
EPREX IV SC 1FL 1ML 40000 UI
ISTITUTO NEUROLOGICO CARLO BESTA
2005 - EUCTR2005-005873-31-IT Italy;
EPREX*1SIR 40000UI/ML 1ML
ISTITUTO NEUROLOGICO CARLO BESTA
2011 - EUCTR2011-001329-26-IT Italy;
2010 - EUCTR2009-016066-91-IT Italy;
Edaravone
Ehime University Hospital
2015 Phase 1,2 JPRN-UMIN000016352 Japan;
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Ferrer Internacional, S.A.
2021 Phase 3 EUCTR2020-003376-40-IE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
Isfahan University of Medical Sciences
2017 Phase 2/Phase 3 NCT03272802 Iran, Islamic Republic of;
Kondo Kazuoki
2022 Phase 3 JPRN-jRCT2071210117 Canada;Germany;Italia;Japan;South Korea;Switzerland;US;
2021 Phase 3 JPRN-jRCT2031200301 Canada;France;Germany;Italy;Japan;Korea;Switzerland;United States of America;
2021 Phase 1 JPRN-jRCT2031200361 Japan;
2020 Phase 3 JPRN-jRCT2041200084 Canada;France;Germany;Italy;Japan;United States of America;
Mitsubishi Tanabe Development America Inc.
2021 Phase 3 EUCTR2019-004256-11-IT Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
2020 Phase 3 EUCTR2019-002108-41-IT Canada;France;Germany;Italy;Japan;United States;
Mitsubishi Tanabe Pharma America Inc.
2019 - NCT04259255 Canada;United States;
Okayama university
2016 - JPRN-UMIN000024854 Japan;
Electrical Impedance Myography
University of Florida
2016 Early Phase 1 NCT02710162 United States;
Endocannabinoid palmitoylethanolamide (PEA)
University of Roma La Sapienza
2014 - NCT02645461 -
Engensis
Helixmith Co., Ltd.
2021 Phase 2 NCT04632225 Korea, Republic of;United States;
Enoxacin
McGill University
2021 Phase 1/Phase 2 NCT04840823 Canada;
Eril®
Georg-August-Universität Göttingen
2019 Phase 2 EUCTR2017-003676-31-FR France;Germany;Switzerland;
Erythropoetin (EPO)
University Hospital Muenster
2006 Phase 2 NCT00298597 Germany;
Erythropoietin
ISTITUTO NEUROLOGICO CARLO BESTA
2005 - EUCTR2005-005873-31-IT Italy;
ISTITUTO NEUROLOGICO CARLO BESTA
2010 - EUCTR2009-016066-91-IT Italy;
Escitalopram
University of South Carolina
2009 Phase 3 NCT00965497 United States;
Ezogabine
Brian Wainger
2015 Phase 2 NCT02450552 United States;
F 18 T807
Tammie L. S. Benzinger, MD, PhD
2015 - NCT02414230 United States;
FAB122
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Ferrer Internacional, S.A.
2022 Phase 3 EUCTR2020-003376-40-SE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
2021 Phase 3 EUCTR2020-003376-40-PL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
2021 Phase 3 EUCTR2020-003376-40-IE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
2021 Phase 3 EUCTR2020-003376-40-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
2021 Phase 3 EUCTR2020-003376-40-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
2021 Phase 3 EUCTR2020-003376-40-BE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Sweden;United Kingdom;
FASUDIL HYDROCHLORIDE
Georg-August-Universität Göttingen
2019 Phase 2 EUCTR2017-003676-31-FR France;Germany;Switzerland;
FLX-787-ODT
Flex Pharma, Inc.
2018 Phase 1/Phase 2 NCT03334786 United States;
FLX-787-ODT (orally disintigrating tablet)
Flex Pharma, Inc.
2017 Phase 1/Phase 2 NCT03338114 United States;
FamC-1
Polski Bank Komórek Macierzystych JSC (PBKM)
2020 Phase 1;Phase 2 EUCTR2018-004171-12-PL Poland;
Fasudil
Peking University Third Hospital
2013 Phase 2 NCT01935518 China;
University Medical Center Goettingen
2019 Phase 2 NCT03792490 France;Germany;Switzerland;
Fasudil (WP-0512)
Woolsey Pharmaceuticals
2021 Phase 2 NCT05218668 Australia;United States;
Febuxostat
Teikyo University
2017 - JPRN-UMIN000029308 Japan;
Tsukuba International Clinical Pharmacology Clinic
2016 - JPRN-UMIN000024312 Japan;
Fecal microbiota transplantation
Azienda Ospedaliero-Universitaria di Modena
2020 - NCT03766321 Italy;
Fenilbutirato
Amylyx Pharmaceuticals Inc.
2021 Phase 3 EUCTR2021-000250-26-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Fig
FeGALS
2009 - JPRN-UMIN000008527 Japan;
Filgrastim
MinYoung Kim, M.D.
2014 - NCT02236065 Korea, Republic of;
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
2014 Phase 2 EUCTR2014-002228-28-IT Italy;
Fixed dose combination Ciprofloxacin/Celecoxib
NeuroSense Therapeutics Ltd.
2019 Phase 2 NCT04165850 Israel;
2019 Phase 1 NCT04090684 United States;
Fycompa
American University of Beirut Medical Center
2019 Phase 2 NCT03377309 Lebanon;
G04CB02
Fundación Universidad Católica de Valencia San Vicente Mártir
2021 Phase 2 NCT04654689 Spain;
GA
TEVA Pharmaceutical Industries. Ltd.
2006 Phase 2 EUCTR2006-001688-49-GB Belgium;Germany;Italy;United Kingdom;
2006 - EUCTR2006-001688-49-DE Belgium;Germany;Italy;United Kingdom;
2006 - EUCTR2006-001688-49-BE Belgium;Germany;Italy;United Kingdom;
GDC-0134
Genentech, Inc.
2016 Phase 1 NCT02655614 Canada;Netherlands;United States;
GM604
Genervon Biopharmaceuticals, LLC
2013 Phase 2 NCT01854294 United States;
GSK1223249
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2012-003349-13-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
GlaxoSmithKline
2009 Phase 1 NCT00875446 France;Italy;United Kingdom;United States;
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2012-003349-13-NL Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2013 - EUCTR2012-003349-13-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 - EUCTR2012-003349-13-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
GUANA2015
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2016 Phase 2 EUCTR2014-005367-32-IT Italy;
GUANABENZ ACETATO
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2016 Phase 2 EUCTR2014-005367-32-IT Italy;
Gilenya
Massachusetts General Hospital
2013 Phase 2 NCT01786174 United States;
Gold
Peking Union Medical College Hospita
2019 - ChiCTR1900024520 China;
Gold Nanocrystals
Clene Nanomedicine
2021 Phase 2 NCT03843710 United States;
Granulocyte - colony stimulating factor (G-CSF)
University Hospital Muenster
2006 Phase 2 NCT00298597 Germany;
Granulocyte Colony Stimulating Factor
Peking University
2006 Phase 2 NCT00397423 China;
Tehran University of Medical Sciences
2012 Phase 2/Phase 3 NCT01825551 Iran, Islamic Republic of;
Growth Hormone (Somatropin)
Federico II University
2007 Phase 2 NCT00635960 Italy;
HB-adMSCs
Hope Biosciences Stem Cell Research Foundation
2020 - NCT04514952 United States;
HK-001
Everfront Biotech Co., Ltd.
2021 Phase 1 NCT03651349 Taiwan;
HUMAN ALBUMIN SOLUTION
Instituto Grifols S.A.
2014 Phase 4 EUCTR2013-004842-40-ES Spain;
HYNR-CS inj
Corestem, Inc.
2011 Phase 1/Phase 2 NCT01363401 Korea, Republic of;
HYNRCS-Allo inj
Hanyang University Seoul Hospital
2017 Phase 1 NCT03214146 Korea, Republic of;
Human Neural Stem Cells
Azienda Ospedaliera Santa Maria, Terni, Italy
2011 Phase 1 NCT01640067 Italy;
Human autologous mesenchymal stem cells
Bioinova, s.r.o.
2012 Phase 2 EUCTR2011-000362-35-CZ Czech Republic;
Huolingshengji Granules
Peking University Third Hospital
2020 Phase 2/Phase 3 NCT04950933 China;
Hyperpolarized [1-13C]pyruvate
Christoffer Laustsen
2020 Phase 2 EUCTR2020-000352-36-DK Denmark;
I-123] ADAM
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2010 - EUCTR2008-003982-21-FR France;
IC14
Implicit Bioscience
2021 Phase 2 NCT04390386 United States;
2019 Phase 2 NCT03508453 Australia;
2019 - NCT04309604 United States;
2017 Phase 1 NCT03487263 Australia;
IC14 (monoclonal antibody against human CD14)
Implicit Bioscience
2019 Phase 2 NCT03474263 Australia;United States;
IFB-088
InFlectis BioScience
2022 Phase 2 EUCTR2021-003875-32-IT France;Italy;
IL-2
Centre Hospitalier Universitaire de Nimes
2017 Phase 2 NCT03039673 France;United Kingdom;
Peking University Third Hospital
2020 Phase 2 NCT04952155 China;
IL-2 per day
Centre Hospitalier Universitaire de Nimes
2015 Phase 2 NCT02059759 France;
ILB
TikoMed AB
2018 Phase 2 NCT03613571 Sweden;
2018 Phase 2 EUCTR2017-005065-47-SE Sweden;
University of Birmingham
2019 Phase 2 NCT03705390 United Kingdom;
ILB: 100mg/ml solution for injection and infusion
University of Birmingham
2018 Phase 2 EUCTR2018-000668-28-GB United Kingdom;
IMMUNOGLOBULIN G
Annexon Biosciences
2021 Phase 2 EUCTR2021-000325-26-FR Canada;France;United States;
INTERLEUKIN-2
Nanjing Hospital Affiliated to Nanjing University of traditional Chinese Medicine
2019 Phase 0 ChiCTR2000035966 China;
ION363
IONIS PHARMACEUTICALS, INC.
- Phase 1;Phase 3 EUCTR2020-005522-28-IT Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Turkey;United Kingdom;United States;
Ionis Pharmaceuticals, Inc.
2021 Phase 3 NCT04768972 Belgium;Canada;United Kingdom;United States;
- Phase 1;Phase 2;Phase 3 EUCTR2020-005522-28-BE Belgium;Canada;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Turkey;United Kingdom;United States;
IPL344
Immunity Pharma Ltd.
2018 Phase 2 NCT03755167 Israel;
2018 Phase 1/Phase 2 NCT03652805 Israel;
ISIS 333611
Isis Pharmaceuticals
2010 Phase 1 NCT01041222 United States;
Ibudilast
MediciNova
2016 Phase 1/Phase 2 NCT02714036 United States;
Icerguastat
InFlectis BioScience
2022 Phase 2 EUCTR2021-003875-32-IT France;Italy;
Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2012-003349-13-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
Immunoglobulin G1, anti (protein Nogo A) (human Mus musculus monoclonal heavy chain), disulfide with human Mus musculus monoclonal light chain, dimer
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2012-003349-13-NL Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2013 - EUCTR2012-003349-13-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 - EUCTR2012-003349-13-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
Incobotulinum Toxin A
Beth Israel Deaconess Medical Center
2012 Phase 2 NCT01565395 United States;
Injection of salivary glands
The University of Texas Health Science Center at San Antonio
2003 Phase 2/Phase 3 NCT00125203 United States;
Inosine
Massachusetts General Hospital
2017 Phase 2 NCT03168711 United States;
2015 Phase 1 NCT02288091 United States;
Teikyo University
2017 - JPRN-UMIN000029308 Japan;
Tsukuba International Clinical Pharmacology Clinic
2016 - JPRN-UMIN000024312 Japan;
Insulin like growth factor, type 1
Mayo Clinic
2003 Phase 3 NCT00035815 Puerto Rico;United States;
Intra venous injection of stem cell
Royan Institute
2013 Phase 1 NCT01759797 Iran, Islamic Republic of;
Intrathecal autologous stem cell
Hospital Universitario Dr. Jose E. Gonzalez
2012 Phase 2/Phase 3 NCT01933321 Mexico;
Intrathecal injection
Royan Institute
2013 Phase 1 NCT01771640 Iran, Islamic Republic of;
Intravenous administration of 1 million of MSC
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
2014 Phase 1/Phase 2 NCT02290886 Spain;
Intravenous administration of 2 million of MSC
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
2014 Phase 1/Phase 2 NCT02290886 Spain;
Intravenous administration of 4 million of MSC
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
2014 Phase 1/Phase 2 NCT02290886 Spain;
Intraventricular injection
Royan Institute
2014 Phase 1 NCT01759784 Iran, Islamic Republic of;
Ioflupane 123I
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2010 - EUCTR2008-003982-21-FR France;
Iowa Oral Performance Instrument
University of Florida
2017 - NCT02962050 United States;
2016 Early Phase 1 NCT02710162 United States;
Iowa Oral Pressure Instrument
University of Florida
2016 Early Phase 1 NCT02710110 United States;
Isocaloric Diet
Fundación Universidad Católica de Valencia San Vicente Mártir
2021 Phase 2 NCT04654689 Spain;
Jevity 1.0
Massachusetts General Hospital
2009 Phase 2 NCT00983983 United States;
Jevity 1.5
Massachusetts General Hospital
2009 Phase 2 NCT00983983 United States;
KNS-760704
Knopp Biosciences
2009 Phase 2 NCT00931944 United States;
2008 Phase 2 NCT00647296 United States;
Ketanest-S
Turku University Hospital
2018 Phase 4 EUCTR2018-000142-18-FI Finland;
KetoCal
Johns Hopkins University
2009 Phase 3 NCT01016522 United States;
L-Serine
Elijah W. Stommel
2018 Phase 2 NCT03580616 United States;
Phoenix Neurological Associates, LTD
2013 Phase 1/Phase 2 NCT01835782 United States;
LAM-002A
AI Therapeutics, Inc.
2021 Phase 2 NCT05163886 United States;
LIORESAL*50CPR
AZIENDA OSPEDALIERO-UNIVERSITARIA
2010 - EUCTR2010-020257-13-IT Italy;
LITIO CARBONATO
AZIENDA OSPEDALIERA PISANA
2009 - EUCTR2009-010060-41-IT Italy;
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2009 - EUCTR2008-006224-61-ES Spain;
Lucia Galan Hospital Clinico San Carlos
2009 - EUCTR2008-005106-38-ES Spain;
Lacosamide
Chiba University
2017 Phase 1/Phase 2 NCT03186040 Japan;
Department of Neurology Chiba University Hospital
2017 - JPRN-UMIN000027476 Japan;
Kuwabara Satoshi
2017 Phase 1-2 JPRN-jRCTs031180173 Japan;
Lactose
FeGALS
2009 - JPRN-UMIN000008527 Japan;
Lamivudine
Stichting TRICALS Foundation
2021 Phase 3 EUCTR2020-005069-15-NL Australia;Netherlands;United Kingdom;
Lenograstim
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2005 - EUCTR2005-003248-75-IT Italy;
Lenzumestrocel
Corestem, Inc.
2021 Phase 3 NCT04745299 Korea, Republic of;
Leuprolide
National Center for Research Resources (NCRR)
1992 Phase 2 NCT00004771 -
Levetiracetam
Duke University
2006 Phase 2 NCT00324454 United States;
Levosimendan
Orion Corporation, Orion Pharma
2019 Phase 3 NCT03948178 Spain;
2018 Phase 3 NCT03505021 Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Lipoic acid group
Second Affiliated Hospital, School of Medicine, Zhejiang University
2020 - NCT04518540 China;
Liposomed polyphenols resveratrol and curcumin
Fundación Universidad Católica de Valencia San Vicente Mártir
2021 Phase 2 NCT04654689 Spain;
Lithium
AZIENDA OSPEDALIERA PISANA
2009 - EUCTR2009-010060-41-IT Italy;
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2008 - EUCTR2008-001094-15-IT Italy;
Assistance Publique - Hôpitaux de Paris
2009 Phase 2 NCT00925847 France;
I.N.M. NEUROMED (I.R.C.C.S.) S.R.L. GIA' SANATRIX
2007 - EUCTR2007-002379-16-IT Italy;
ISTITUTO SUPERIORE DI SANITA`
2009 - EUCTR2008-006722-34-IT Italy;
Lithium Apogepha
King's College London
2009 Phase 4 EUCTR2008-006891-31-GB United Kingdom;
Lithium carbonate
Forbes Norris MDA/ALS Research Center
2008 Phase 2 NCT00790582 United States;
Lithiumcarbonaat 400 PCH tabletten
Prof. dr L.H. van den Berg, UMC-Utrecht
2008 - EUCTR2008-002110-22-NL Netherlands;
Lunasin Regimen
Richard Bedlack, M.D., Ph.D.
2016 Phase 2 NCT02709330 United States;
MANNITOLO LDB
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
2014 Phase 2 EUCTR2014-002228-28-IT Italy;
MCI-186
Mitsubishi Tanabe Pharma Corporation
2007 Phase 3 NCT00424463 Japan;
2006 Phase 3 NCT00415519 Japan;
2006 Phase 3 NCT00330681 Japan;
MCI-186 in open label phase
Mitsubishi Tanabe Pharma Corporation
2011 Phase 3 NCT01492686 Japan;
MD1003
MEDDAY PHARMACEUTICALS
2016 Phase 2 EUCTR2015-005810-31-FR France;
MedDay Pharmaceuticals SA
2016 Phase 2 NCT03114215 France;
MEMANTINE HYDROCHLORIDE
Jorge Matias-Guiu Guia
2008 - EUCTR2007-002117-39-ES Spain;
MN-166
MediciNova
2020 Phase 2/Phase 3 NCT04057898 Canada;United States;
2014 Phase 2 NCT02238626 United States;
MediciNova, Inc.
2020 Phase 2;Phase 3 EUCTR2019-003549-14-HU Germany;Greece;Hungary;Italy;Poland;Spain;United States;
MNC (Mononuclear cells)
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
2021 Phase 2 NCT04849065 Spain;
Red de Terapia Celular
2014 Phase 1 NCT02286011 Spain;
MSC-NTF cells transplantation (IM)
Brainstorm-Cell Therapeutics
2011 Phase 1/Phase 2 NCT01051882 Israel;
MSC-NTF cells transplantation (IT)
Brainstorm-Cell Therapeutics
2011 Phase 1/Phase 2 NCT01051882 Israel;
MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF
Brainstorm-Cell Therapeutics
2012 Phase 2 NCT01777646 Israel;
MT-1186
Mitsubishi Tanabe Development America Inc.
2021 Phase 3 EUCTR2020-000376-38-IT Canada;France;Germany;Italy;Japan;United States;
2021 Phase 3 EUCTR2019-004256-11-IT Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
2020 Phase 3 EUCTR2019-002108-41-IT Canada;France;Germany;Italy;Japan;United States;
Mitsubishi Tanabe Pharma Corporation
2020 Phase 1 NCT04254913 Japan;
2019 Phase 1 NCT04176224 Japan;
Mitsubishi Tanabe Pharma Development America, Inc.
2021 Phase 3 EUCTR2020-000376-38-DE Canada;France;Germany;Italy;Japan;United States;
2020 Phase 3 NCT04577404 Canada;France;Germany;Italy;Japan;United States;
2020 Phase 3 NCT04569084 Canada;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
2020 Phase 3 EUCTR2019-002108-41-DE Canada;France;Germany;Italy;Japan;United States;
Mitsubishi Tanabe Pharma Development America, Inc. (MTDA)
2021 Phase 3 EUCTR2019-004256-11-DE Canada;France;Germany;Italy;Japan;Korea, Republic of;Switzerland;United States;
MYELOSTIM 34*1FL 263MCG+1SIR
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2005 - EUCTR2005-003248-75-IT Italy;
MYONAL*30CPR RIV
AZIENDA OSPEDALIERO-UNIVERSITARIA
2010 - EUCTR2010-020257-13-IT Italy;
Masitinib (3.0)
AB Science
2013 Phase 2/Phase 3 NCT02588677 Spain;
Masitinib (4.5)
AB Science
2020 Phase 3 NCT03127267 Canada;Germany;United States;
2013 Phase 2/Phase 3 NCT02588677 Spain;
Masitinib (6.0)
AB Science
2020 Phase 3 NCT03127267 Canada;Germany;United States;
Masitinib 100 mg Tablets
AB Science
- Phase 2;Phase 3 EUCTR2010-024423-24-IE Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
Masitinib 200 mg Tablets
AB Science
- Phase 2;Phase 3 EUCTR2010-024423-24-IE Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
Masitinib mesilate
AB SCIENCE
2021 Phase 3 EUCTR2019-001862-13-IT Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
Masitinib mesylate
AB Science
2022 Phase 3 EUCTR2019-001862-13-GR Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001862-13-DK Argentina;Belgium;Canada;Denmark;France;Ireland;Israel;Italy;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-PL Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
- Phase 2;Phase 3 EUCTR2010-024423-24-IE Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
ABScience
2022 Phase 3 EUCTR2019-001862-13-PT Argentina;Belgium;Canada;Denmark;France;Germany;Greece;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2019-001862-13-NO Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-SI Argentina;Austria;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-SE Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2020 Phase 3 EUCTR2019-001862-13-ES Argentina;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Netherlands;Norway;Poland;Portugal;Russian Federation;Slovenia;Spain;Sweden;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-PT Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-NL Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-HU Argentina;Belgium;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Mexico;Netherlands;Poland;Portugal;Romania;Serbia;Slovakia;Spain;Taiwan;United Kingdom;United States;
2015 Phase 2;Phase 3 EUCTR2010-024423-24-GR Argentina;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;United Kingdom;United States;
2014 Phase 2;Phase 3 EUCTR2010-024423-24-SK Argentina;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Serbia;Slovakia;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2010-024423-24-ES France;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Slovakia;Spain;
MediCabilis CBD Oil
Gold Coast Hospital and Health Service
2019 Phase 3 NCT03690791 Australia;
Medicine
Center for iPS Cell Research and Application (CiRA), Kyoto University
2019 Phase 1 JPRN-JMA-IIA00419 Japan;
Memantine
Phoenix Neurological Associates, LTD
2005 Phase 2 NCT01020331 United States;
University of Alberta
2007 Phase 2 NCT00409721 Canada;
University of Kansas Medical Center
2018 Phase 2 NCT02118727 United States;
Memantine (Ebixa)
University of Lisbon
2005 Phase 2/Phase 3 NCT00353665 Portugal;
Memantine Hydrochloride Oral Solution
University of Edinburgh
2020 Phase 2/Phase 3 NCT04302870 United Kingdom;
Mesenchymal stem cell
Alzahra Hospital, Iran
2015 Phase 1/Phase 2 NCT02116634 Iran, Islamic Republic of;
Mesenchymal stem cells
Royan Institute
2014 Phase 1 NCT02492516 Iran, Islamic Republic of;
Mesenchymal stem cells (MSC)
Hadassah Medical Organization
2016 Phase 1/Phase 2 NCT04821479 -
Mesenchymal stem cells isolated from Wharton's jelly
Polski Bank Komorek Macierzystych JSC (PBKM)
2020 Phase 1/Phase 2 NCT04651855 Poland;
Metformin
University of Florida
2020 Phase 2 NCT04220021 United States;
Methylcobalamin
University of Tokushima
2017 Phase 3 NCT03548311 Japan;
Methylphenylpyrazolone
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Methylprednisolone
Emory University
2013 Phase 2 NCT01884571 United States;
Mexiletine
Bjorn Oskarsson, MD
2013 Phase 4 NCT01811355 United States;
Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
2011 - JPRN-UMIN000006423 Japan;
University of Washington
2016 Phase 2 NCT02781454 United States;
2013 Phase 2 NCT01849770 United States;
Micro Mouth Pressure Meter
University of Florida
2016 Early Phase 1 NCT02710162 United States;
2016 Early Phase 1 NCT02710110 United States;
Midazolam
Genentech, Inc.
2016 Phase 1 NCT02655614 Canada;Netherlands;United States;
Minocycline
Columbia University
2006 Phase 2 NCT00355576 United States;
National Institute of Neurological Disorders and Stroke (NINDS)
2003 Phase 3 NCT00047723 United States;
Modal
Oregon Health and Science University
2021 - NCT04468919 United States;
Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections
The Methodist Hospital Research Institute
2019 Phase 2 NCT04055623 United States;
Moxifloxacin
Knopp Biosciences
2012 Phase 1 NCT01511029 United States;
Multiple Dose
Knopp Biosciences
2011 Phase 1 NCT01424163 United Kingdom;
Mycophenolate mofetil
Emory University
2013 Phase 2 NCT01884571 United States;
NP001
Neuraltus Pharmaceuticals, Inc.
2016 Phase 2 NCT02794857 Canada;United States;
2011 Phase 2 NCT01281631 United States;
2010 Phase 1 NCT01091142 United States;
Norantipyrine
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Norphenazone
Ferrer Internacional S.A.
2021 Phase 3 EUCTR2020-003376-40-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;
Nuedexta
Center for Neurologic Study, La Jolla, California,
2013 Phase 2 NCT01806857 United States;
NurOwn® (MSC-NTF cells)
Brainstorm-Cell Therapeutics
2017 Phase 3 NCT03280056 United States;
ODM-109
ORION CORPORATION ORION PHARMA
2019 Phase 3 EUCTR2018-004180-31-IT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-IT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Orion Corporation
2020 Phase 3 EUCTR2018-004180-31-FR Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-NL Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-IE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-GB Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-FI Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-ES Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-DE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-BE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-AT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002754-36-FR Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-NL Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-IE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-GB Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-FI Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-ES Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-BE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-AT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Orion Corporation, Orion Pharma
2015 Phase 2 NCT02487407 Germany;Ireland;Netherlands;United Kingdom;
ODM-109 capsule
Orion Corporation Orion Pharma
2015 Phase 2 EUCTR2014-004567-21-NL Germany;Ireland;Netherlands;United Kingdom;
2015 Phase 2 EUCTR2014-004567-21-IE Germany;Ireland;Netherlands;United Kingdom;
2015 Phase 2 EUCTR2014-004567-21-GB Germany;Ireland;Netherlands;United Kingdom;
2015 Phase 2 EUCTR2014-004567-21-DE Germany;Ireland;Netherlands;United Kingdom;
ONO-2506
ONO PHARMA UK LTD
2007 - EUCTR2006-002660-26-IT Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
ONO-2506PO
ONO PHARMA UK LTD
2004 - EUCTR2004-002912-27-ES Spain;
ONO Pharmaceutical Co., Ltd.
2008 Phase 2 EUCTR2007-004723-37-FR Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-GB Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-DE Belgium;France;Germany;United Kingdom;
2008 - EUCTR2007-004723-37-BE Belgium;France;Germany;United Kingdom;
ONO Pharmaceutical Co.,Ltd
2007 - EUCTR2006-002660-26-NL Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2007 - EUCTR2006-002660-26-GB Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 Phase 2 EUCTR2006-002660-26-FR Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-DE Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-BE Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
2006 - EUCTR2006-002660-26-AT Austria;Belgium;France;Germany;Italy;Netherlands;United Kingdom;
Ono Pharmaceutical Co. Ltd
2008 Phase 2 NCT00694941 Belgium;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
2006 Phase 2 NCT00403104 Austria;Belgium;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;
Olanzapine
Charite University, Berlin, Germany
2011 Phase 2/Phase 3 NCT00876772 Germany;
Olesoxime
Hoffmann-La Roche
2009 Phase 3 NCT00868166 Belgium;France;Germany;Netherlands;Spain;United Kingdom;
TROPHOS
2011 - EUCTR2010-021179-10-GB Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-GB Belgium;France;Germany;Spain;United Kingdom;
TROPHOS SA
2011 Phase 2;Phase 3 EUCTR2010-021179-10-BE Belgium;Germany;Spain;United Kingdom;
2011 - EUCTR2010-021179-10-DE Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-FR Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-BE Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-007320-25-ES Belgium;France;Germany;Spain;United Kingdom;
2009 - EUCTR2008-007320-25-DE Belgium;France;Germany;Spain;United Kingdom;
Oral LEVOSIMENDAN
ORION CORPORATION ORION PHARMA
2019 Phase 3 EUCTR2018-004180-31-IT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-IT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Orion Corporation
2020 Phase 3 EUCTR2018-004180-31-FR Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-NL Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-IE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-GB Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-FI Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-ES Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-DE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-BE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2018-004180-31-AT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2017-002754-36-FR Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-NL Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-IE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-GB Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-FI Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-ES Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-BE Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2017-002754-36-AT Australia;Austria;Belgium;Canada;Finland;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Oral nutritional supplementation
University Hospital, Limoges
2014 - NCT02152449 France;
Oxepa
Massachusetts General Hospital
2009 Phase 2 NCT00983983 United States;
Ozanezumab
GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
2012 - EUCTR2012-003349-13-IT Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
GlaxoSmithKline
2012 Phase 2 NCT01753076 Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
GlaxoSmithKline Research and Development Limited
2013 - EUCTR2012-003349-13-NL Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2013 - EUCTR2012-003349-13-DE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-GB Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 Phase 2 EUCTR2012-003349-13-FR Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
2012 - EUCTR2012-003349-13-BE Australia;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Netherlands;United Kingdom;United States;
PARACETAMOLO
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
2014 Phase 2 EUCTR2014-002228-28-IT Italy;
PBMC autotransplantation
The First Affiliated Hospital of Dalian Medical University
2010 - NCT03085706 China;
PERFALGAN
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
2014 Phase 2 EUCTR2014-002228-28-IT Italy;
PLENUR
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2009 - EUCTR2008-006224-61-ES Spain;
Lucia Galan Hospital Clinico San Carlos
2009 - EUCTR2008-005106-38-ES Spain;
PU-AD
Samus Therapeutics, Inc.
2021 Phase 2 NCT04505358 -
Pegcetacoplam
APELLIS PHARMACEUTCIALS, INC.
2021 Phase 2 EUCTR2019-003797-10-IT Argentina;Australia;Belgium;Brazil;Czech Republic;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Pegcetacoplan (APL-2)
Apellis Pharmaceuticals, Inc.
2020 Phase 2 NCT04579666 Australia;Belgium;Czechia;France;Germany;Ireland;Italy;Japan;Netherlands;Poland;Spain;Ukraine;United Kingdom;United States;
Perampanel
Department of Neurology, Juntendo University School of Medicine
2017 Phase 1 JPRN-UMIN000026221 Japan;
Department of Neurology, Tokyo Medical University
2017 Phase 2 JPRN-UMIN000025614 Japan;
Mayo Clinic
2018 Early Phase 1 NCT03793868 United States;
Stony Brook University
2017 - NCT03020797 United States;
Tokyo Medical University
2017 Phase 2 NCT03019419 Japan;
Phenylbutyrate
Amylyx Pharmaceuticals Inc.
2022 Phase 3 EUCTR2021-000250-26-PL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Pimozide 2 mg per day
University of Calgary
2015 Phase 2 NCT02463825 Canada;
Pimozide 2mg/day (current) or 4 mg/day (study initiation)
University of Calgary
2017 Phase 2 NCT03272503 Canada;
Pimozide 4 mg per day
University of Calgary
2015 Phase 2 NCT02463825 Canada;
Pioglitazone
University Hospital of Ulm
2008 - EUCTR2006-005410-13-DE Germany;
University of Ulm
2008 Phase 2 NCT00690118 Germany;Italy;
Pioglitazone and Tretinoin
Phoenix Neurological Associates, LTD
2008 Phase 1/Phase 2 NCT00919555 United States;
Plasma from healthy young people treatment + Riluzole
Peking University Third Hospital
2016 Early Phase 1 NCT04454840 China;
PolyMVA
University of Missouri-Columbia
2020 Phase 1 NCT04557410 United States;
PowerLung trainer
University of Florida
2016 Early Phase 1 NCT02710110 United States;
Prednisone
Emory University
2013 Phase 2 NCT01884571 United States;
Pridopidine
Merit E. Cudkowicz, MD
2020 Phase 2/Phase 3 NCT04615923 United States;
2020 Phase 2/Phase 3 NCT04297683 United States;
Probiotic
Avera McKennan Hospital & University Health Center
2017 - NCT03324399 United States;
Proleukin 18 MUI
CHU DE NIMES
2016 Phase 2 EUCTR2015-005347-14-GB United Kingdom;
Prototype capsule GDC-0134
Genentech, Inc.
2017 Phase 1 NCT03237741 United Kingdom;
Pulmonary Function Testing
University of Florida
2017 - NCT02962050 United States;
2016 Early Phase 1 NCT02710162 United States;
2016 Early Phase 1 NCT02710110 United States;
Pyrimethamine
Weill Medical College of Cornell University
2009 Phase 1/Phase 2 NCT01083667 Germany;Italy;Sweden;United States;
Q-Cells
Q Therapeutics, Inc.
2021 Phase 1/Phase 2 NCT02478450 -
R(+) pramipexole dihydrochloride monohydrate
Bennett, James P., Jr., M.D., Ph.D.
2007 Phase 1/Phase 2 NCT00600873 United States;
2005 Phase 1/Phase 2 NCT00140218 United States;
2005 - NCT00596115 -
RA15804589, C19061501-F, DNL788, DN2489, DN0002489
Sanofi-aventis recherche & développement
2022 Phase 2 EUCTR2021-004156-42-NL Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
2022 Phase 2 EUCTR2021-004156-42-ES Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
2022 Phase 2 EUCTR2021-004156-42-BE Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
RAPA-501 Autologous T cells
Rapa Therapeutics LLC
2020 Phase 1/Phase 2 NCT04220190 United States;
RAPAMUNE - 1 MG 100 COMPRESSE RIVESTITE IN BLISTER USO ORALE
AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA
2017 Phase 2 EUCTR2016-002399-28-IT Italy;
RILUTEK 50 mg, film-coated tablets
Aventis Pharma Ltd.
2004 - EUCTR2004-002390-23-DE Germany;
RILUZOLO
FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA
2016 Phase 2 EUCTR2014-005367-32-IT Italy;
RNS60
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
2017 Phase 2 EUCTR2016-002382-62-IT Italy;United States;
Mario Negri Institute for Pharmacological Research
2016 Phase 2 NCT03456882 Italy;United States;
Revalesio Corporation
2022 Phase 2 NCT02988297 -
Sabrina Paganoni, M.D.
2015 Phase 1 NCT02525471 United States;
RT001
Retrotope, Inc.
2021 Phase 2 NCT04762589 Estonia;Latvia;Netherlands;Sweden;
2021 Phase 2 EUCTR2020-003962-38-SE Estonia;Netherlands;Sweden;
2021 Phase 2 EUCTR2020-003962-38-NL Estonia;Netherlands;Sweden;
2021 Phase 2 EUCTR2020-003962-38-EE Estonia;Netherlands;Sweden;
RYAH-Medtech Inhaler
OMNI Medical Services, LLC
2018 Phase 2 NCT03944447 United States;
Rabeprazole
Genentech, Inc.
2017 Phase 1 NCT03237741 United Kingdom;
2016 Phase 1 NCT02655614 Canada;Netherlands;United States;
Ranolazine
University of Kansas Medical Center
2018 Phase 2 NCT03472950 United States;
Rapamycin
Azienda Ospedaliero-Universitaria di Modena
2017 Phase 2 NCT03359538 Italy;
Rasagiline
Richard Barohn, MD
2013 Phase 2 NCT01786603 United States;
University of Ulm
2013 Phase 2 NCT01879241 Germany;
Yunxia Wang, MD
2011 Phase 2 NCT01232738 Canada;United States;
Ravulizumab
Alexion Pharmaceuticals
2020 Phase 3 NCT04248465 Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Recombinant human erythropoietin(rhEPO)
Hanyang University Seoul Hospital
2016 Phase 1/Phase 2 NCT03835507 Korea, Republic of;
Reference capsule GDC-0134
Genentech, Inc.
2017 Phase 1 NCT03237741 United Kingdom;
Reldesemtiv
CYTOKINETICS, INC.
2021 Phase 3 EUCTR2020-004040-29-IT Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
Cytokinetics
2021 Phase 3 NCT04944784 Australia;Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2017 Phase 2 NCT03160898 Australia;Canada;Ireland;Netherlands;Spain;United States;
Cytokinetics, Inc.
2018 Phase 2 EUCTR2018-000586-37-NL Australia;Canada;Ireland;Netherlands;Spain;United States;
2018 Phase 2 EUCTR2018-000586-37-IE Australia;Canada;Ireland;Netherlands;Spain;United States;
2018 Phase 2 EUCTR2018-000586-37-ES Australia;Canada;Ireland;Netherlands;Spain;United States;
Repository corticotropin injection
Mallinckrodt
2013 Phase 2 NCT01906658 United States;
Requip CR tablets
none
2018 Phase 1-2 JPRN-JMA-IIA00397 Japan;
Rilutek
Cytokinetics Inc
2013 Phase 2 EUCTR2012-004987-23-GB Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-004987-23-ES Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-IE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-DE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
- - EUCTR2012-004987-23-NL Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
Rilutek 50 mg film-coated tablets
Centre for Human Drug Research
2015 Phase 2 EUCTR2015-001431-20-NL Netherlands;
Riluzole
AB Science
2020 Phase 3 NCT03127267 Canada;Germany;United States;
2013 Phase 2/Phase 3 NCT02588677 Spain;
AZIENDA OSPEDALIERA PISANA
2009 - EUCTR2009-010060-41-IT Italy;
Aventis Pharma Ltd.
2004 - EUCTR2004-002390-23-DE Germany;
Biohaven Pharmaceuticals, Inc.
2018 - NCT03537807 -
Centre Hospitalier Universitaire de Nimes
2017 Phase 2 NCT03039673 France;United Kingdom;
Corestem, Inc.
2021 Phase 3 NCT04745299 Korea, Republic of;
Cytokinetics
2012 Phase 2 NCT01709149 Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2011 Phase 2 NCT01486849 United States;
Department of Neurology, Graduate School of Medicine, Chiba University, Japan.
2011 - JPRN-UMIN000006423 Japan;
Guangdong Province Traditional Chinese Medical Hospital
2014 - ChiCTR-IOR-14005674 China;
Hoffmann-La Roche
2009 Phase 3 NCT00868166 Belgium;France;Germany;Netherlands;Spain;United Kingdom;
Isfahan University of Medical Sciences
2017 Phase 2/Phase 3 NCT03272802 Iran, Islamic Republic of;
Massachusetts General Hospital
2009 Phase 2/Phase 3 NCT00818389 Canada;United States;
MediciNova
2014 Phase 2 NCT02238626 United States;
Peking University Third Hospital
2021 Phase 2 ChiCTR2100044085 China;
Sanofi
2001 Phase 4 NCT00542412 Canada;
Shanghai Sixth People's Hospital
2020 Phase 0 ChiCTR2000035988 China;
University Affiliated Sixth People's Hospital
2021 Phase 0 ChiCTR2000028960 China;
University of Lisbon
2005 Phase 2/Phase 3 NCT00353665 Portugal;
University of Roma La Sapienza
2014 - NCT02645461 -
Riluzole (100 mg)
GENUV Inc.
2020 Phase 1/Phase 2 NCT04326283 Korea, Republic of;
Riluzole 50 MG (Part B)
Cytokinetics
2011 Phase 2 NCT01378676 United States;
Riluzole Oral Soluble Film
Aquestive Therapeutics
2018 Phase 2 NCT03457753 United States;
Riluzole Oral Soluble film (ROSF)
Aquestive Therapeutics
2018 Phase 2 NCT03679975 United States;
Riluzole tablet
Peking University Third Hospital
2020 Phase 2/Phase 3 NCT04950933 China;
Ritonavir
National Institute of Neurological Disorders and Stroke (NINDS)
2019 Phase 1 NCT02437110 United States;
SAR443820
Sanofi
2022 Phase 2 NCT05237284 -
Sanofi-aventis recherche & développement
2022 Phase 2 EUCTR2021-004156-42-NL Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
2022 Phase 2 EUCTR2021-004156-42-ES Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
2022 Phase 2 EUCTR2021-004156-42-BE Belgium;Canada;China;France;Germany;Italy;Japan;Netherlands;Spain;Sweden;United Kingdom;United States;
SB-509
Sangamo Biosciences
2008 Phase 2 NCT00748501 United States;
SLS-005
Merit E. Cudkowicz, MD
2022 Phase 2/Phase 3 NCT05136885 -
SLS-005 Trehalose
Merit E. Cudkowicz, MD
2020 Phase 2/Phase 3 NCT04297683 United States;
SNN0029
Newron Sweden AB
2014 Phase 1 NCT01999803 Belgium;Netherlands;
2009 Phase 1/Phase 2 NCT01384162 Belgium;
2008 Phase 1/Phase 2 NCT00800501 Belgium;
SNN0029 infusion solution
Newron Sweden AB
2015 Phase 1 NCT02269436 Belgium;Netherlands;
SODIUM PYRUVATE
Christoffer Laustsen
2020 Phase 2 EUCTR2020-000352-36-DK Denmark;
SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
Assistance Publique - Hôpitaux de Paris
2012 Phase 3 NCT01160263 France;
SUB126308
AB Science
- Phase 2;Phase 3 EUCTR2010-024423-24-IE Argentina;Belgium;Colombia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Netherlands;Portugal;Romania;Slovakia;Spain;Switzerland;United Kingdom;United States;
Saline solution
University of Tokushima
2017 Phase 3 NCT03548311 Japan;
Sativex
FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
2011 - EUCTR2010-022808-40-IT Italy;
Scopolamine
Mie University Graduate school of medicine,Department of neurology
2013 - JPRN-UMIN000011494 Japan;
Scopolamine, atropine, edaravone and dexmedetomidine
Ruijin Hospital
2020 Phase 2 NCT04391361 China;
Selective Serotonin Uptake Inhibitors (SSRI)
St. Louis University
2015 Early Phase 1 NCT02851914 United States;
Single dose reduced
Knopp Biosciences
2011 Phase 1 NCT01424163 United Kingdom;
Single dose standard
Knopp Biosciences
2011 Phase 1 NCT01424163 United Kingdom;
Sodio phenylbutyrate
AMYLYX PHARMACEUTICALS Inc.
2021 Phase 3 EUCTR2021-000250-26-IT Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Sodium Valproate
UMC Utrecht
2005 Phase 3 NCT00136110 Netherlands;
Sodium phenylbutyrate
Department of Veterans Affairs
2005 Phase 1/Phase 2 NCT00107770 United States;
Spirit1
Herb Spirit
2021 Phase 1 NCT02588807 Israel;
Stem Cell
Neurogen Brain and Spine Institute
2008 Phase 1 NCT02242071 India;
Stem Cells
Stem Cells Arabia
2016 Phase 1/Phase 2 NCT03067857 -
Stem cell
Neurogen Brain and Spine Institute
2008 Phase 2 NCT01984814 India;
Stem cell (HPC) implantation
Cedars-Sinai Medical Center
2017 Phase 1 NCT02943850 United States;
Stereotactic surgical device
Cedars-Sinai Medical Center
2017 Phase 1 NCT02943850 United States;
Suspension of human autologous MSC 3P in 1,5 ml
Bioinova, s.r.o.
2012 Phase 2 EUCTR2011-000362-35-CZ Czech Republic;
Suspension of human autologous MSC 3P in 1.5 ml
Bioinova, s.r.o.
2012 Phase 1/Phase 2 NCT03828123 -
Synthetic stereopure antisense oligonucleotide targeting human C9orf72 hexanucleotide repeat-containing mRNA transcripts
Wave Life Sciences UK Limited
2022 Phase 1;Phase 2 EUCTR2020-005193-94-SE Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
2022 Phase 1;Phase 2 EUCTR2020-005193-94-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
TCH346
NOVARTIS FARMA
2004 - EUCTR2004-002855-15-IT Germany;Italy;United Kingdom;
Novartis
2004 Phase 2 NCT00230074 United States;
Novartis Pharma Services AG
2004 - EUCTR2004-002855-15-GB Germany;Italy;United Kingdom;
2004 - EUCTR2004-002855-15-DE Germany;Italy;United Kingdom;
Novartis Pharmaceuticals
2003 Phase 2 NCT00072709 Belgium;Canada;France;Germany;Italy;Netherlands;Switzerland;United Kingdom;United States;
2002 Phase 2 NCT00036413 United States;
TEVAGRASTIM
Università degli Studi di Torino e Azienda Ospedaliera Città della Salute e della Scienza di Torino
2014 Phase 2 EUCTR2014-002228-28-IT Italy;
TJ-68
Hiroshi Mitsumoto
2021 Phase 1/Phase 2 NCT04998305 United States;
TPN-101
Transposon Therapeutics, Inc
2022 Phase 2 EUCTR2021-002251-11-ES Belgium;Canada;France;Germany;Netherlands;Spain;United Kingdom;United States;
TPN-101, 400 mg/day
Transposon Therapeutics, Inc.
2021 Phase 2 NCT04993755 France;United States;
TRO19622
Hoffmann-La Roche
2010 Phase 2/Phase 3 NCT01285583 Belgium;France;Germany;Spain;United Kingdom;
TROPHOS
2011 - EUCTR2010-021179-10-GB Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-GB Belgium;France;Germany;Spain;United Kingdom;
TROPHOS SA
2011 Phase 2;Phase 3 EUCTR2010-021179-10-BE Belgium;Germany;Spain;United Kingdom;
2011 - EUCTR2010-021179-10-DE Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-FR Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2;Phase 3 EUCTR2008-007320-25-BE Belgium;France;Germany;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-007320-25-ES Belgium;France;Germany;Spain;United Kingdom;
2009 - EUCTR2008-007320-25-DE Belgium;France;Germany;Spain;United Kingdom;
TUDCA
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2018-002722-22-IT Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom;
TUDCABIL
Humanitas Mirasole SpA
2019 Phase 3 EUCTR2018-002722-22-NL Belgium;Germany;Italy;Netherlands;United Kingdom;
2019 Phase 3 EUCTR2018-002722-22-DE Belgium;Germany;Italy;Netherlands;United Kingdom;
2019 Phase 3 EUCTR2018-002722-22-BE Belgium;Germany;Italy;Netherlands;United Kingdom;
IRCCS ISTITUTO CLINICO HUMANITAS
2018 Phase 3 EUCTR2018-002722-22-IT Belgium;France;Germany;Ireland;Italy;Netherlands;United Kingdom;
TV-7110
Teva Pharmaceutical Industries, Ltd
2008 Phase 2 EUCTR2008-002062-62-FR Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 Phase 2 EUCTR2008-002062-62-ES Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-NL Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-HU Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-DE Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-BE Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Teva Pharmaceutical Industries,Ltd
2008 - EUCTR2008-002062-62-IT Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Tacrolimus
Emory University
2013 Phase 2 NCT01884571 United States;
Talampanel
Teva Pharmaceutical Industries
2009 Phase 2 NCT00982150 Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States;
2008 Phase 2 NCT00696332 Belgium;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Spain;United States;
Teva Pharmaceutical Industries, Ltd
2008 Phase 2 EUCTR2008-002062-62-FR Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 Phase 2 EUCTR2008-002062-62-ES Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-NL Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-HU Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-DE Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
2008 - EUCTR2008-002062-62-BE Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Teva Pharmaceutical Industries,Ltd
2008 - EUCTR2008-002062-62-IT Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Tallampanel
Teva Pharmaceutical Industries,Ltd
2008 - EUCTR2008-002062-62-IT Belgium;France;Germany;Hungary;Italy;Netherlands;Spain;
Tamoxifen
Nazem Atassi
2011 Phase 2 NCT01257581 United States;
University of Wisconsin, Madison
2001 Phase 2 NCT00214110 United States;
Tamoxifen 40 mg daily for one year
Taipei Medical University Shuang Ho Hospital
2014 Phase 1/Phase 2 NCT02166944 Taiwan;
Taurolite
IRCCS ISTITUTO CLINICO HUMANITAS
2019 Phase 3 EUCTR2018-002722-22-GB Netherlands;United Kingdom;
Tauroursodeoxycholic acid
IRCCS ISTITUTO CLINICO HUMANITAS
2019 Phase 3 EUCTR2018-002722-22-GB Netherlands;United Kingdom;
ISTITUTO NEUROLOGICO CARLO BESTA
2008 - EUCTR2007-001592-10-IT Italy;
Tauroursodeoxycholic acid (TUDCA)
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
2008 Phase 2 NCT00877604 Italy;
Taurursodiol
Amylyx Pharmaceuticals Inc.
2022 Phase 3 EUCTR2021-000250-26-PL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-SE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Tenofovir alafenamide (TAF)
National Institute of Neurological Disorders and Stroke (NINDS)
2019 Phase 1 NCT02437110 United States;
Testosterone
National Center for Research Resources (NCRR)
1992 Phase 2 NCT00004771 -
Thalidomide
Dartmouth-Hitchcock Medical Center
2005 Phase 2 NCT00140452 United States;
Thalidomide (drug)
Charite University, Berlin, Germany
2005 Phase 2 NCT00231140 Germany;
Theracurmin HP
Richard Bedlack, M.D., Ph.D.
2020 Phase 2 NCT04499963 United States;
Tioctic acid
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
2006 - EUCTR2005-005152-40-IT Italy;
Tirasemtiv
CYTOKINETICS, INC.
2016 Phase 3 EUCTR2014-005413-23-IT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Cytokinetics
2016 Phase 3 NCT02936635 Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 NCT02496767 Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Cytokinetics Inc
2013 Phase 2 EUCTR2012-004987-23-GB Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 Phase 2 EUCTR2012-004987-23-ES Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-IE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
2013 - EUCTR2012-004987-23-DE Canada;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
- - EUCTR2012-004987-23-NL Canada;France;Germany;Ireland;Netherlands;Spain;United Kingdom;United States;
Cytokinetics, Inc.
2017 Phase 3 EUCTR2016-002629-13-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-FR Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-ES Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002629-13-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-PT Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-NL Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-IE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-ES Belgium;Canada;France;Germany;Ireland;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-DE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2014-005413-23-BE Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2014-005413-23-GB Belgium;Canada;France;Germany;Ireland;Italy;Netherlands;Portugal;Spain;United Kingdom;United States;
Tocilizumab
Barrow Neurological Institute
2015 Phase 2 NCT02469896 United States;
Tocotrienols
University of Malaya
2019 Phase 2 NCT04140136 Malaysia;
Tofersen
BIOGEN IDEC RESEARCH LIMITED
2022 Phase 3 EUCTR2020-004590-51-IT Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Biogen Idec Research Limited
2021 Phase 3 EUCTR2020-004590-51-FR Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004590-51-ES Australia;Belgium;Brazil;Bulgaria;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2020-004590-51-DE Australia;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2016-003225-41-ES Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2016-003225-41-DK Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2020 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-DK Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
2018 Phase 3 EUCTR2016-003225-41-DE Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;New Zealand;Poland;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003225-41-BE Australia;Belgium;Canada;Denmark;European Union;Germany;Israel;Italy;Japan;Korea, Republic of;Poland;Spain;United Kingdom;United States;
2016 Phase 1;Phase 2;Phase 3 EUCTR2015-004098-33-DE Australia;Belgium;Canada;Denmark;France;Germany;Italy;Japan;Poland;Sweden;United Kingdom;United States;
Trametinib (0.5 mg)
GENUV Inc.
2020 Phase 1/Phase 2 NCT04326283 Korea, Republic of;
Trametinib (1 mg)
GENUV Inc.
2020 Phase 1/Phase 2 NCT04326283 Korea, Republic of;
Trametinib (2 mg)
GENUV Inc.
2020 Phase 1/Phase 2 NCT04326283 Korea, Republic of;
Trazodone Hydrochloride oral solution
University of Edinburgh
2020 Phase 2/Phase 3 NCT04302870 United Kingdom;
Tretinoin and Pioglitazone HCL
Phoenix Neurological Associates, LTD
2008 Phase 1/Phase 2 NCT00919555 United States;
Tricyclic Antidepressants (TCA)
St. Louis University
2015 Early Phase 1 NCT02851914 United States;
Triheptanoin
Richard Bedlack, M.D., Ph.D.
2018 Phase 1/Phase 2 NCT03506425 United States;
Trimetazidine
The University of Queensland
2021 Phase 2 EUCTR2020-005018-17-NL Australia;Netherlands;
Trimetazidine Dihydrochloride
The University of Queensland
2021 Phase 2 NCT04788745 Australia;Netherlands;United Kingdom;
Triumeq
Neuroscience Trials Australia
2016 Phase 2 NCT02868580 Australia;
Stichting TRICALS Foundation
2021 Phase 3 EUCTR2020-005069-15-NL Australia;Netherlands;United Kingdom;
Trobalt
Centre for Human Drug Research
2015 Phase 2 EUCTR2015-001431-20-NL Netherlands;
Téralithe LP
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2008 - EUCTR2008-003707-32-FR France;
Ultomiris
ALEXION PHARMACEUTICALS INCORPORATED
2020 Phase 3 EUCTR2019-004619-30-IT Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Alexion Pharmaceuticals
2020 Phase 3 EUCTR2019-004619-30-SE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-NL Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-IE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-GB Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-FR Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-ES Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Korea, Republic of;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-DK Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
2020 Phase 3 EUCTR2019-004619-30-DE Australia;Belgium;Canada;Denmark;France;Germany;Ireland;Israel;Italy;Japan;Netherlands;Poland;Spain;Sweden;Switzerland;United Kingdom;United States;
Ultra-high-caloric carbohydrate-rich diet
Albert Christian Ludolph, Prof.
2019 Phase 1 NCT04172792 Germany;
Ultra-high-caloric fatty diet
Albert Christian Ludolph, Prof.
2019 Phase 1 NCT04172792 Germany;
Umbilical cord blood therapy
MinYoung Kim, M.D.
2014 - NCT02236065 Korea, Republic of;
Ursodoxicoltaurina
Amylyx Pharmaceuticals Inc.
2021 Phase 3 EUCTR2021-000250-26-ES Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
Ursodoxicoltaurine
Amylyx Pharmaceuticals Inc.
2022 Phase 3 EUCTR2021-000250-26-PL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-SE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-NL Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-FR Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
2021 Phase 3 EUCTR2021-000250-26-DE Belgium;France;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
VM202
Helixmith Co., Ltd.
2014 Phase 1/Phase 2 NCT02039401 United States;
Vastarel
The University of Queensland
2021 Phase 2 EUCTR2020-005018-17-NL Australia;Netherlands;
Verdiperstat
Merit E. Cudkowicz, MD
2020 Phase 2/Phase 3 NCT04436510 United States;
2020 Phase 2/Phase 3 NCT04297683 United States;
Videofluoroscopic Swallowing Study
University of Florida
2016 Early Phase 1 NCT02710162 United States;
Videofluoroscopic Swallowing Study (VFSS)
University of Florida
2017 - NCT02962050 United States;
Videofluoroscopic swallowing study
University of Florida
2016 Early Phase 1 NCT02710110 United States;
Vitamin E
Lawson Health Research Institute
2006 Phase 3 NCT00372879 Canada;
Voluntary Peak Cough Flow Testing
University of Florida
2017 - NCT02962050 United States;
WHARTON’S JELLY-DERIVED MESENCHYMAL STEM CELLS
Polski Bank Komórek Macierzystych JSC (PBKM)
2020 Phase 1;Phase 2 EUCTR2018-004171-12-PL Poland;
WVE-004
Wave Life Sciences Ltd.
2021 Phase 1/Phase 2 NCT04931862 Australia;Canada;Ireland;Netherlands;United Kingdom;
Wave Life Sciences UK Limited
2022 Phase 1;Phase 2 EUCTR2020-005193-94-SE Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
2022 Phase 1;Phase 2 EUCTR2020-005193-94-BE Australia;Belgium;Canada;Germany;Ireland;Netherlands;New Zealand;Sweden;United Kingdom;United States;
Water
Clinical Research Hospital Tokyo
2014 - JPRN-UMIN000015054 Japan;
National Hospital Organization Takasaki General Medical Center
2015 - JPRN-UMIN000019111 Japan;
Withania somnifera
Sunnybrook Health Sciences Centre
2021 Phase 2 NCT05031351 -
YAM80
Yoshino Neurology Clinic
2009 Phase 2 NCT00886977 Japan;
ZIBREN*20BUST
IST. DI RICERCHE FARMACOLOG. M. NEGRI
2005 - EUCTR2004-004158-23-IT Italy;
Zilucoplan
Merit E. Cudkowicz, MD
2020 Phase 2/Phase 3 NCT04436497 United States;
2020 Phase 2/Phase 3 NCT04297683 United States;
Zinc and Copper
Phoenix Neurological Associates, LTD
2010 Phase 1/Phase 2 NCT01259050 United States;
Zyprexa
Charité – Universitätsmedizin Berlin
2008 - EUCTR2007-003775-39-DE Germany;
[11C]CPPC Injection
Johns Hopkins University
2021 Phase 1 NCT04749433 United States;
[11C]MPC6827
Columbia University
2021 Early Phase 1 NCT04575727 United States;
[18F] GE-180
Massachusetts General Hospital
2015 - NCT02559869 United States;
[18F]DPA-714 PET
University Hospital, Tours
2015 Early Phase 1 NCT02405403 France;
[18F]PBR06
Molecular NeuroImaging
2016 Phase 1 NCT03876002 United States;
glatiramer acetate
TEVA Pharmaceutical Industries. Ltd.
2006 Phase 2 EUCTR2006-001688-49-GB Belgium;Germany;Italy;United Kingdom;
2006 - EUCTR2006-001688-49-DE Belgium;Germany;Italy;United Kingdom;
2006 - EUCTR2006-001688-49-BE Belgium;Germany;Italy;United Kingdom;
Teva Pharmaceutical Industries, Ltd.
2006 Phase 2 NCT00326625 Belgium;France;Germany;Israel;Italy;United Kingdom;
glucose water solution
Centre Hospitalier Universitaire de Nimes
2017 Phase 2 NCT03039673 France;United Kingdom;